Triazole derivative

ABSTRACT

A compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof has an effect of inhibiting binding between S1P and its receptor Edg-1(S1P 1 ), and is useful as a pharmaceutical product. 
     
       
         
         
             
             
         
       
         
         
           
             [where 
             A represents a sulfur atom, an oxygen atom, a formula —SO— or a formula —SO 2 —; R 1  represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or the like; R 2  represents an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms or the like; R 3  represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R 4  represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a phenyl group or the like; R 5  represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and R 6  represents an alkyl group having 1 to 6 carbon atoms, a phenyl group or a substituted phenyl group].

TECHNICAL FIELD

This invention relates to novel triazole derivatives having the effectof inhibiting binding between sphingosine-1-phosphate having variousphysiological actions and Edg-1 (Endothelial differentiation genereceptor type-1, S1P₁), which is one of its receptors, andpharmaceutical products containing them as active ingredients.

BACKGROUND ART

Sphingosine-1-phosphate (hereinafter referred to as “S1P”) is aphysiologically active lipid which is produced upon metabolism, incells, of sphingolipids typified by sphingomyelin. S1P is known to havewide varieties of actions, including a cell differentiation inducingaction, a cell growth promoting action, control of cell motility, and anantiapoptotic action, and to show physiological actions such asangiogenesis, induction of bradycardia, activation of inflammatorycells, and activation of platelets (non-patent document 1).

Five subtypes, Edg-1(S1P₁), Edg-3(S1P₃), Edg-5(S1P₂), Edg-6(S1P₄), andEdg-8(S1P₅), are reported as receptors of S1P (non-patent document 2).

One of them, Edg-1(S1P₁), is expressed in large amounts in immune cellssuch as T cells and dendritic cells, and the vascular endothelial cells,and is suggested to contribute deeply to S1P-associated migration of Tcells (non-patent document 3), migration of mast cells (non-patentdocument 4), emigration of T cells and B cells from lymph organs(non-patent document 5), and angiogenesis (non-patent document 6), andto be involved in autoimmune diseases such as Crohn disease, irritablecolitis, Sjögren syndrome, multiple sclerosis, and systemic lupuserythematosus, and diseases such as rheumatoid arthritis, asthma, atopicdermatitis, rejection reaction after organ transplantation, cancer,retinopathy, psoriasis, osteoarthrosis, and age-related maculardegeneration.

Thus, Edg-1(S1P₁) ligands are considered to be effective for thetreatment or prevention of these diseases.

So far, certain types of thiophene derivatives (non-patent document 7),phosphate ester derivatives (patent document 1, patent document 2,non-patent document 8), and thiazolidine derivatives (patent document 3)have been reported as Edg-1(S1P₁) ligands. However, inhibitors havingstructures similar to the structure of the compound of the presentinvention have not been known.

Compounds similar in structure to the compound of the present inventionare marketed as reagents by Bionet, but their pharmaceutical uses arecompletely unknown.

Patent document 1: WO02/18395

-   -   Patent document 2: Japanese Unexamined Patent Publication No.        2003-137894    -   Patent document 3: Japanese Unexamined Patent Publication No.        2002-332278    -   Non-patent document 1: J Biol Chem. 2004, 279:20555, FASEB J        2002, 16:625, Proceedings of the Japanese Society of Immunology        2003, 33:2-J-W30-20-P    -   Non-patent document 2: Pharmacol Res 2003, 47:401    -   Non-patent document 3: FASEB J 2002, 16:1874    -   Non-patent document 4: J Exp Med 2004, 199:959    -   Non-patent document 5: Nature 2004, 427:355    -   Non-patent document 6: J Clin Invest 2000, 106:951, Biocchim        Biophys Acta 2002, 1582:222    -   Non-patent document 7: J Biol Chem 2004, 279:13839    -   Non-patent document 8: Bioorg Med Chem Lett 2003, 13:3401

DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention

It is an object of the present invention to provide a compound which hasthe effect of inhibiting binding between S1P and its receptorEdg-1(S1P₁) and is useful as a pharmaceutical product.

Means for Solving the Problems

The inventors diligently conducted studies in an attempt to find ligandcompounds for Edg-1(S1P₁). As a result, they have found that certaintypes of triazole derivatives or their pharmaceutically acceptable saltsattain this object. This finding has led to the accomplishment of thepresent invention.

That is, the present invention is a compound represented by the formula(I) below or a pharmaceutically acceptable salt thereof

{where

-   -   A represents a sulfur atom, an oxygen atom, a group represented        by the formula —SO—, or a group represented by the formula        —SO₂—,    -   R¹ represents a hydrogen atom, an alkyl group having 1 to 16        carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an        alkynyl group having 2 to 8 carbon atoms, [an alkyl group having        1 to 6 carbon atoms which has been substituted by a phenyl        group, “a phenyl group substituted by 1 to 5 groups selected        from a phenyl group, a cyano group, a halogen atom, an alkyl        group having 1 to 6 carbon atoms, a trifluoromethyl group, a        methoxycarbonyl group, an alkylthio group having 1 to 6 carbon        atoms, a dimethylamino group, a nitro group, and an acetamido        group”, a cycloalkyl group having 3 to 8 carbon atoms, a        hydroxyl group, an alkylthio group having 1 to 6 carbon atoms,        an alkoxy group having 1 to 6 carbon atoms, a benzyloxy group, a        phenoxy group, a trifluoromethyl group, a difluoromethyl group,        a benzenesulfonyl group, a naphthyl group, a tricycloalkyl group        having 7 to 10 carbon atoms, a carbomethoxy(phenyl)methyl group,        a diphenylmethyl group, a 1-phenylethyl group, an imidazolyl        group, an indolyl group, a pyridyl group, an oxetanyl group, an        oxoranyl group, a methylpiperidinyl group, a benzylpiperidinyl        group, a morpholino group, a 2-oxopyrrolidin-1-yl group, a        2-oxoimidazolidin-1-yl group, a group represented by the formula        —CO₂R¹¹    -   where R¹¹ represents a hydrogen atom or an alkyl group having 1        to 6 carbon atoms,        a group represented by the formula

-   -   where R¹² and R¹³ each represent a hydrogen atom or an alkyl        group having 1 to 6 carbon atoms,        a group represented by the formula

-   -   where R¹⁴ and R¹⁵ each represent a hydrogen atom, an alkyl group        having 1 to 6 carbon atoms, a phenyl group, or a        4-pyridylcarbonyl group,        or a group represented by the formula        —COR¹⁶    -   where R¹⁶ represents an alkyl group having 1 to 6 carbon atoms,        or a phenyl group],        an alkenyl group having 2 to 8 carbon atoms which has been        substituted by a phenyl group or a benzyloxy group, an alkynyl        group having 2 to 8 carbon atoms which has been substituted by a        phenyl group, a cycloalkyl group having 3 to 8 carbon atoms, a        cycloalkyl group having 3 to 8 carbon atoms in which the benzene        rings have been condensed, an oxoranyl group, a        methylpiperidinyl group, or a group represented by the formula

R² represents an alkyl group having 1 to 6 carbon atoms, a cycloalkylgroup having 3 to 8 carbon atoms, a phenyl group, or [an alkyl grouphaving 1 to 6 carbon atoms which has been substituted by a phenyl group,an alkoxy group having 1 to 6 carbon atoms, a morpholino group, apiperidino group, a group represented by the formula

-   -   where R²¹ represents a hydrogen atom or an alkyl group having 1        to 6 carbon atoms,        or a group represented by the formula

-   -   where R²² and R²³ each represent a hydrogen atom or an alkyl        group having 1 to 6 carbon atoms],    -   R³ represents a hydrogen atom or an alkyl group having 1 to 6        carbon atoms,    -   R⁴ represents a hydrogen atom, an alkyl group having 1 to 6        carbon atoms, a benzyl group, a substituted benzyl group, a        phenethyl group, “an alkyl group having 1 to 6 carbon atoms        which has been substituted by an alkoxy group having 1 to 6        carbon atoms, a halogen atom or a hydroxyl group”, or a phenyl        group, or    -   R³ and R⁴ together form a 3- to 6-membered saturated hydrocarbon        ring,    -   R⁵ represents a hydrogen atom or an alkyl group having 1 to 6        carbon atoms, and    -   Y represents a group represented by the formula

where R⁶ represents an alkyl group having 1 to 10 carbon atoms, analkenyl group having 2 to 8 carbon atoms, “an alkyl group having 1 to 10carbon atoms which has been substituted by 1 to 5 groups selected from aphenyl group, a substituted phenyl group, a cycloalkyl group having 3 to8 carbon atoms, a halogen atom, a naphthyl group, a heterocyclic group,and a substituted heterocyclic group”, “an alkenyl group having 2 to 8carbon atoms which has been substituted by 1 to 5 groups selected from aphenyl group, a substituted phenyl group, a cycloalkyl group having 3 to8 carbon atoms, a halogen atom, a naphthyl group, a heterocyclic group,and a substituted heterocyclic group”, a phenyl group, a substitutedphenyl group, a naphthyl group, a naphthyl group substituted by adimethylamino group, a heterocyclic group, or a substituted heterocyclicgroup,

with the exception of [the compound in which A is an oxygen atom, and R¹is a hydrogen atom], [the compound in which A is a sulfur atom, and R¹is a hydrogen atom], [the compound in which A is a sulfur atom, and R³and R⁴ are each a hydrogen atom at the same time], [the compound inwhich A is a sulfur atom, and R² is a phenyl group], [the compound inwhich A is a sulfur atom, R² is an ethyl group, R³ and R⁵ are each ahydrogen atom, R⁴ is a benzyl group, R⁶ is a 4-fluorophenyl group, andR¹ is a 3-methoxybenzyl group], [the compound in which A is a sulfuratom, R² is an ethyl group, R³ and R⁵ are each a hydrogen atom, R⁴ is abenzyl group, R⁶ is a 4-fluorophenyl group, and R¹ is a 3-fluorobenzylgroup], [the compound in which A is a sulfur atom, R² is an ethyl group,R³ and R⁵ are each a hydrogen atom, R⁴ is a benzyl group, R⁶ is a4-fluorophenyl group, and R¹ is a 2-propenyl group], [the compound inwhich A is a sulfur atom, R² is an ethyl group, R³ and R⁵ are each ahydrogen atom, R⁴ is a benzyl group, R⁶ is a 4-fluorophenyl group, andR¹ is a 4-t-butylbenzyl group], [the compound in which A is a sulfuratom, R² is an ethyl group, R³ and R⁵ are each a hydrogen atom, R⁴ is abenzyl group, R⁶ is a 4-fluorophenyl group, and R¹ is a methyl group],[the compound in which A is a sulfur atom, R² is an ethyl group, R³ andR⁵ are each a hydrogen atom, R⁴ is a methyl group, R⁶ is a4-chlorophenyl group, and R¹ is a methyl group], [the compound in whichA is a sulfur atom, R² is an ethyl group, R³ and R⁵ are each a hydrogenatom, R⁴ is a methyl group, R⁶ is a 4-chlorophenyl group, and R¹ is a2-propenyl group], [the compound in which A is a sulfur atom, R² is anethyl group, R³ and R⁵ are each a hydrogen atom, R⁴ is a methyl group,R⁶ is a 4-chlorophenyl group, and R¹ is a 4-methoxybenzyl group], [thecompound in which A is a sulfur atom, R² is an ethyl group, R³ and R⁵are each a hydrogen atom, R⁴ is a methyl group, R⁶ is a 4-chlorophenylgroup, and R¹ is a 4-t-butylbenzyl group], [the compound in which A is asulfur atom, R² is an ethyl group, R³ and R⁵ are each a hydrogen atom,R⁴ is a methyl group, R⁶ is a 4-chlorophenyl group, and R¹ is a3,4-dichlorobenzyl group], [the compound in which A is a sulfur atom, R²is an ethyl group, R³ and R⁵ are each a hydrogen atom, R⁴ is a methylgroup, R⁶ is a 4-chlorophenyl group, and R¹ is a 2-chlorobenzyl group],[the compound in which A is a sulfur atom, R² is an ethyl group, R³ andR⁵ are each a hydrogen atom, R⁴ is a methyl group, R⁶ is a4-chlorophenyl group, and R¹ is a 3-fluorobenzyl group], [the compoundin which A is a sulfur atom, R² is a methyl group, R³ and R⁵ are each ahydrogen atom, R⁴ is a benzyl group, R⁶ is a 4-chlorophenyl group, andR¹ is a 2-methyl-2-propenyl group], [the compound in which A is a sulfuratom, R² is a methyl group, R³ and R⁵ are each a hydrogen atom, R⁴ is abenzyl group, R⁶ is a 4-chlorophenyl group, and R¹ is a 2-propenylgroup], [the compound in which A is a sulfur atom, R² is a methyl group,R³ and R⁵ are each a hydrogen atom, R⁴ is a benzyl group, R⁶ is a4-chlorophenyl group, and R¹ is a methoxycarbonylmethyl group], [thecompound in which A is a sulfur atom, R² is a methyl group, R³ and R⁵are each a hydrogen atom, R⁴ is a benzyl group, R⁶ is a 4-chlorophenylgroup, and R¹ is a 4-trifluoromethylbenzyl group], [the compound inwhich A is a sulfur atom, R² is a methyl group, R³ and R⁵ are each ahydrogen atom, R⁴ is a benzyl group, R⁶ is a 4-chlorophenyl group, andR¹ is a 3,4-dichlorobenzyl group], [the compound in which A is a sulfuratom, R² is a methyl group, R³ and R⁵ are each a hydrogen atom, R⁴ is abenzyl group, R⁶ is a 4-chlorophenyl group, and R¹ is a 4-bromobenzylgroup], and [the compound in which A is a sulfur atom, R² is an ethylgroup, R³ and R⁵ are each a hydrogen atom, R⁴ is a benzyl group, R⁶ is a4-fluorophenyl group, and R¹ is a 4-methylbenzyl group]}.

Another aspect of the present invention is a pharmaceutical productcomprising a compound represented by the formula (I) below or apharmaceutically acceptable salt thereof as an active ingredient:

{where

-   -   A represents a sulfur atom, an oxygen atom, a group represented        by the formula —SO—, or a group represented by the formula        —SO₂—,    -   R¹ represents a hydrogen atom, an alkyl group having 1 to 16        carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an        alkynyl group having 2 to 8 carbon atoms, [an alkyl group having        1 to 6 carbon atoms which has been substituted by a phenyl        group, “a phenyl group substituted by 1 to 5 groups selected        from a phenyl group, a cyano group, a halogen atom, an alkyl        group having 1 to 6 carbon atoms, a trifluoromethyl group, a        methoxycarbonyl group, an alkylthio group having 1 to 6 carbon        atoms, a dimethylamino group, a nitro group, and an acetamido        group”, a cycloalkyl group having 3 to 8 carbon atoms, a        hydroxyl group, an alkylthio group having 1 to 6 carbon atoms,        an alkoxy group having 1 to 6 carbon atoms, a benzyloxy group, a        phenoxy group, a trifluoromethyl group, a difluoromethyl group,        a benzenesulfonyl group, a naphthyl group, a tricycloalkyl group        having 7 to 10 carbon atoms, a carbomethoxy(phenyl)methyl group,        a diphenylmethyl group, a 1-phenylethyl group, an imidazolyl        group, an indolyl group, a pyridyl group, an oxetanyl group, an        oxoranyl group, a methylpiperidinyl group, a benzylpiperidinyl        group, a morpholino group, a 2-oxopyrrolidin-1-yl group, a        2-oxoimidazolidin-1-yl group, a group represented by the formula        —CO₂R¹¹    -   where R¹¹ represents a hydrogen atom or an alkyl group having 1        to 6 carbon atoms,        a group represented by the formula

-   -   where R¹² and R¹³ each represent a hydrogen atom or an alkyl        group having 1 to 6 carbon atoms,        a group represented by the formula

-   -   where R¹⁴ and R¹⁵ each represent a hydrogen atom, an alkyl group        having 1 to 6 carbon atoms, a phenyl group, or a        4-pyridylcarbonyl group,        or a group represented by the formula        —COR¹⁶    -   where R¹⁶ represents an alkyl group having 1 to 6 carbon atoms,        or a phenyl group],        an alkenyl group having 2 to 8 carbon atoms which has been        substituted by a phenyl group or a benzyloxy group, an alkynyl        group having 2 to 8 carbon atoms which has been substituted by a        phenyl group, a cycloalkyl group having 3 to 8 carbon atoms, a        cycloalkyl group having 3 to 8 carbon atoms in which the benzene        rings have been condensed, an oxoranyl group, a        methylpiperidinyl group, or a group represented by the formula

R² represents an alkyl group having 1 to 6 carbon atoms, a cycloalkylgroup having 3 to 8 carbon atoms, a phenyl group, or [an alkyl grouphaving 1 to 6 carbon atoms which has been substituted by a phenyl group,an alkoxy group having 1 to 6 carbon atoms, a morpholino group, apiperidino group, a group represented by the formula

-   -   where R²¹ represents a hydrogen atom or an alkyl group having 1        to 6 carbon atoms,        or a group represented by the formula

-   -   where R²² and R²³ each represent a hydrogen atom or an alkyl        group having 1 to 6 carbon atoms],    -   R³ represents a hydrogen atom or an alkyl group having 1 to 6        carbon atoms,    -   R⁴ represents a hydrogen atom, an alkyl group having 1 to 6        carbon atoms, a benzyl group, a substituted benzyl group, a        phenethyl group, “an alkyl group having 1 to 6 carbon atoms        which has been substituted by an alkoxy group having 1 to 6        carbon atoms, a halogen atom or a hydroxyl group”, or a phenyl        group, or    -   R³ and R⁴ together form a 3- to 6-membered saturated hydrocarbon        ring,    -   R⁵ represents a hydrogen atom or an alkyl group having 1 to 6        carbon atoms, and    -   Y represents a group represented by the formula

where R⁶ represents an alkyl group having 1 to 10 carbon atoms, analkenyl group having 2 to 8 carbon atoms, “an alkyl group having 1 to 10carbon atoms which has been substituted by 1 to 5 groups selected from aphenyl group, a substituted phenyl group, a cycloalkyl group having 3 to8 carbon atoms, a halogen atom, a naphthyl group, a heterocyclic group,and a substituted heterocyclic group”, “an alkenyl group having 2 to 8carbon atoms which has been substituted by 1 to 5 groups selected from aphenyl group, a substituted phenyl group, a cycloalkyl group having 3 to8 carbon atoms, a halogen atom, a naphthyl group, a heterocyclic group,and a substituted heterocyclic group”, a phenyl group, a substitutedphenyl group, a naphthyl group, a naphthyl group substituted by adimethylamino group, a heterocyclic group, or a substituted heterocyclicgroup}.

Still another aspect of the present invention is the compound of theformula (I) or the pharmaceutically acceptable salt thereof according toclaim 1 wherein the portion corresponding to Y is a hydrogen atom, A isan oxygen atom, and R⁵ is a hydrogen atom, and is an intermediate usefulfor producing the compound of the formula (I).

In the present invention, the alkyl group having 1 to 16 carbon atomsrefers to a straight-chain or branched-chain alkyl group having 1 to 16carbon atoms. Its examples are a methyl group, an ethyl group, ann-propyl group, an isopropyl group, an n-butyl group, an isobutyl group,a tert-butyl group, a sec-butyl group, an n-pentyl group, an isopentylgroup, a neopentyl group, a tert-pentyl group, an n-hexyl group, ann-heptyl, an n-octyl group, and an n-hexadecyl group.

The alkyl group having 1 to 6 carbon atoms refers to a straight-chain orbranched-chain alkyl group having 1 to 6 carbon atoms. Its examples area methyl group, an ethyl group, an n-propyl group, an isopropyl group,an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butylgroup, an n-pentyl group, an isopentyl group, a neopentyl group, atert-pentyl group, and an n-hexyl group.

The alkyl group having 1 to 4 carbon atoms refers to a straight-chain orbranched-chain alkyl group having 1 to 4 carbon atoms. Its examples area methyl group, an ethyl group, an n-propyl group, an isopropyl group,an n-butyl group, an isobutyl group, a tert-butyl group, and a sec-butylgroup.

The alkenyl group having 2 to 8 carbon atoms refers to a straight-chainor branched-chain alkenyl group having 2 to 8 carbon atoms. Its examplesare a vinyl group, an allyl group, a 1-propenyl group, an isopropenylgroup, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a1,3-butadienyl group, a 2-methylallyl group, a 2-methyl-propenyl group,a 2-pentenyl group, and a 3-methyl-but-2-enyl group.

The alkenyl group having 3 to 5 carbon atoms refers to a straight-chainor branched-chain alkenyl group having 3 to 5 carbon atoms. Its examplesare an allyl group, a 1-propenyl group, an isopropenyl group, a1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1,3-butadienylgroup, a 2-methylallyl group, a 2-methyl-propenyl group, and a4-pentenyl group.

The alkynyl group having 2 to 8 carbon atoms refers to a straight-chainor branched-chain alkynyl group having 2 to 8 carbon atoms. Its examplesare an ethynyl group, a 2-propynyl group, a 2-butynyl group, a1-methyl-prop-2-ynyl group, a 2-pentynyl group, and a 4-pentynyl group.

The cycloalkyl group having 3 to 8 carbon atoms refers to a cycloalkylgroup having 3 to 8 carbon atoms, and its examples are a cyclopropylgroup, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, acycloheptyl group, and a cyclooctyl group.

The cycloalkyl group having 3 to 6 carbon atoms refers to a cycloalkylgroup having 3 to 6 carbon atoms, and its examples are a cyclopropylgroup, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.

The halogen atom refers to a fluorine atom, a chlorine atom, a bromineatom, or an iodine atom.

The alkylthio group having 1 to 6 carbon atoms refers to astraight-chain or branched-chain alkylthio group having 1 to 6 carbonatoms. Its examples are a methylthio group, an ethylthio group, apropylthio group, an isopropylthio group, a butylthio group, anisobutylthio group, a pentylthio group, a hexylthio group, and anallylthio group.

The alkoxy group having 1 to 6 carbon atoms refers to a straight-chainor branched-chain alkoxy group having 1 to 6 carbon atoms. Its examplesare a methoxy group, an ethoxy group, a propoxy group, an isopropoxygroup, a butoxy group, an isobutoxy group, a sec-butoxy group, atert-butoxy group, a pentyloxy group, a hexyloxy group, and an allyloxygroup.

The cycloalkyl group having 3 to 8 carbon atoms refers to a cycloalkylgroup having 3 to 8 carbon atoms, and its examples are a cyclopropylgroup, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, acycloheptyl group, and a cyclooctyl group.

The tricycloalkyl group having 7 to 10 carbon atoms refers to atricycloalkyl group having 7 to 10 carbon atoms, and includes, forexample, an adamantyl group.

The cycloalkyl group having 3 to 8 carbon atoms in which the benzenerings have been condensed includes, for example, a1,2,3,4-tetrahydronaphthalenyl group, and an indanyl group.

The substituted benzyl group refers to a benzyl group substituted by (1to 2 groups selected from a phenyl group, a halogen atom, a methylgroup, a methoxy group, a trifluoromethyl group, or a hydroxyl group).Its examples are a 4-phenylbenzyl group, a 3,4-dichlorobenzyl group, a4-methylbenzyl group, and a 4-methoxybenzyl group.

As the 3- to 6-membered saturated hydrocarbon ring, cyclopropane,cyclobutane, cyclopentane, and cyclohexane can be named.

The alkyl group having 1 to 10 carbon atoms refers to a straight-chainor branched-chain alkyl group having 1 to 10 carbon atoms. Its examplesare a methyl group, an ethyl group, an n-propyl group, an isopropylgroup, an n-butyl group, an isobutyl group, a tert-butyl group, asec-butyl group, an n-pentyl group, an isopentyl group, a neopentylgroup, a tert-pentyl group, an n-hexyl group, and an n-decyl group.

The substituted phenyl group refers to a phenyl group substituted by 1to 5 groups selected, for example, from a phenyl group, a methoxy group,a phenyl group substituted by an acetyl group, an oxazolyl group, apyrazolyl group, a methylpyrimidinyl group, a cyano group, a halogenatom, an alkyl group having 1 to 6 carbon atoms, a trifluoromethylgroup, a hydroxyl group, an alkoxy group having 1 to 6 carbon atoms, acyanoethoxy group, a phenoxy group, a phenoxy group substituted by amethoxy group, a pyridinyloxy group, an acetyl group, a benzoyl group, apyridinecarbonyl group, a methoxycarbonyl group, a methoxycarbonylethylgroup, an alkylthio group having 1 to 6 carbon atoms, a dimethylaminogroup, a nitro group, an acetamido group, a sulfamoyl group, amethanesulfonyl group, a benzenesulfonyl group, a pyrrolidinesulfonylgroup, a morpholinesulfonyl group, a methylureido group, a butylureidogroup, a methoxyethylureido group, a trimethylureido group, amorpholinecarbonylamino group, and a pyridinylethoxycarbonylamino group.

The heterocyclic group refers to a saturated or unsaturated monocyclicor polycyclic heterocyclic group having 1 to 6 hetero-atoms such as anoxygen atom, a sulfur atom, and a nitrogen atom. Its examples are animidazolyl group, a pyrazolyl group, a thiazolyl group, an oxazolylgroup, an isoxazolyl group, a furyl group, a thienyl group, a pyrrolylgroup, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, anindolyl group, a quinolyl group, an isoquinolyl group, a benzofuranylgroup, a benzothienyl group, a dihydrobenzofuranyl group, a cumarinylgroup, a 2,3-dihydrobenzo[1,4]dioxinyl group, a3,4-dihydro-2H-benzo[b][1,4]dioxepinyl group, a benzo[1,3]dioxolylgroup, a 2-oxo-2,3-dihydrobenzoxazolyl group, a benzo[1,2,5]thiadiazolylgroup, a 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazinyl group, and aphthalimido group.

The substituted heterocyclic group refers to the above-mentionedheterocyclic group substituted by 1 to 5 substituents selected from ahalogen atom, an alkyl group having 1 to 6 carbon atoms, amethoxycarbonyl group, a benzenesulfonyl group, and an oxazolyl group.

The pharmaceutically acceptable salt refers to a salt with an alkalimetal, an alkaline earth metal, ammonium, an alkylammonium or the like,or a salt with a mineral acid or an organic acid. Its examples are asodium salt, a potassium salt, a calcium salt, an ammonium salt, analuminum salt, a triethylammonium salt, an acetate, a propionate, abutyrate, a formate, a trifluoroacetate, a maleate, a tartrate, acitrate, a stearate, a succinate, an ethylsuccinate, a lactobionate, agluconate, a glucoheptonate, a benzoate, a methanesulfonate, anethanesulfonate, a 2-hydroxyethanesulfonate, a benzenesulfonate, ap-toluenesulfonate, a lauryl sulfate, a malate, an aspartate, aglutamate, an adipate, a salt with cysteine, a salt withN-acetylcysteine, a hydrochloride, a hydrobromide, a phosphate, asulfate, a hydroiodide, a nicotinate, an oxalate, a picrate, athiocyanate, an undecanoate, a salt with an acrylic polymer, and a saltwith a carboxyvinyl polymer.

The compound of the present invention may be present as a stereoisomersuch as an optical isomer, a diastereomer, or a geometric isomer. All ofthese stereoisomers and their mixtures are included in the compounds ofthe present invention.

The compound of the present invention can be synthesized, for example,by the methods shown below.

-   -   (1) A compound represented by the following formula (a)

where R³ and R⁴ are as defined above, is reacted with a compoundrepresented by the formula R′OH (where R′ represents an alkyl grouphaving 1 to 6 carbon atoms) in the presence of a reagent such astrimethylsilyl chloride. Then, the product is reacted with a compoundrepresented by the following formula (b)

where R⁶ is as defined above,

in a solvent, or without a solvent, in the presence of a base to obtaina compound represented by the following formula (c)

where R³, R⁴, R⁶ and R′ are as defined above.

-   -   (2) The compound represented by the formula (c) is reacted with        hydrazine in a solvent or under solventless conditions to obtain        a compound represented by the following formula (d)

where R³, R⁴ and R⁶ are as defined above.

-   -   (3) The resulting compound (d) is reacted with a compound        represented by the following formula (e)        R²—N═C═S  (e)    -   where R² is as defined above,        in a solvent or under solventless conditions to obtain a        compound represented by the following formula (f)

where R², R³, R⁴ and R⁶ are as defined above.

-   -   (4) The resulting compound (f) is cyclized by a base in a        solvent or under solventless conditions to obtain a compound        represented by the following formula (g)

where R², R³, R⁴ and R⁶ are as defined above.

-   -   (5) The resulting compound (g) is reacted with a compound        represented by the following formula (h)        R¹⁸-L  (h)    -   where R¹⁸ has the same meaning as that of the aforementioned R¹        with the exception of a hydrogen atom, and L represents a        leaving group, the leaving group referring, for example, to a        halogen atom such as a chlorine atom, a bromine atom, or an        iodine atom, or an alkylsulfonyloxy group or an arylsulfonyloxy        group such as a methanesulfonyloxy group or a        p-toluenesulfonyloxy group,        in a solvent or under solventless conditions in the presence of        a base, whereby the compound of the present invention        represented by the following formula (i)

where R¹⁸, R², R³, R⁴ and R⁶ are as defined above, can be synthesized.

-   -   (6) Also, the compound of the present invention represented by        the above formula (i) is reacted with a compound represented by        the following formula (j)        R⁵¹-L  (j)    -   where R⁵¹ represents an alkyl group having 1 to 6 carbon atoms,        and L is as defined above,        in a solvent or under solventless conditions in the presence of        a base, whereby there can be synthesized another compound of the        present invention represented by the following formula (k)

where R¹⁸, R², R³, R⁴, R⁵¹ and R⁶ are as defined above.

-   -   (7) Further, the compound represented by the formula (i) or (k)        above is reacted with an oxidizing agent in a solvent, whereby        still another compound of the present invention represented by        the following formula (l)

where R¹⁸, R², R³, R⁴, R⁵ and R⁶ are as defined above, can besynthesized.

-   -   (8) Then, the compound represented by the above formula (l) is        reacted with a compound represented by the formula        R¹⁸-A¹-H  (m)    -   where A¹ represents a sulfur atom or an oxygen atom, and R¹⁸ is        as defined above,        in a solvent or under solventless conditions in the presence of        a base, whereby yet another compound of the present invention        represented by the following formula (n)

where A¹, R¹⁸, R², R³, R⁴, R⁵ and R⁶ are as defined above,

can be synthesized.

Alternatively, the compound of the present invention can be synthesizedby the method shown below.

-   -   (2-1) A compound represented by the following formula (o)

-   -   where R″ represents a protective group for an amino group, such        as a t-butoxycarbonyl group or a benzyloxycarbonyl group, and        R³, R⁴, and R′ are as defined above,        is reacted with hydrazine in a solvent or under solventless        conditions to obtain a compound represented by the following        formula (p)

where R³, R⁴ and R″ are as defined above.

-   -   (2-2) The resulting compound of the formula (p) is reacted with        a compound represented by the following formula (e)        R²—N═C═S  (e)    -   where R² is as defined above,        in a solvent or under solventless conditions to obtain a        compound represented by the following formula (q)

where R², R³, R⁴ and R″ are as defined above.

-   -   (2-3) The resulting compound of the formula (q) is cyclized by a        base in a solvent or under solventless conditions to obtain a        compound represented by the formula (r)

where R², R³, R⁴ and R″ are as defined above.

-   -   (2-4) The resulting compound of the formula (r) is reacted with        a compound represented by the following formula (h)        R¹⁸-L  (h)    -   where R¹⁸ and L are as defined above,        in a solvent or under solventless conditions in the presence of        a base to obtain a compound represented by the following formula        (s)

where R¹⁸, R², R³, R⁴ and R″ are as defined above.

-   -   (2-5) The resulting compound of the formula (s) is reacted with        an oxidizing agent in a solvent to obtain a compound represented        by the following formula (t)

where R¹⁸, R², R³, R⁴ and R″ are as defined above.

-   -   (2-6) The resulting compound of the formula (t) is subjected to        deprotection of the amino group under ordinary conditions, such        as reaction with an acid, in a solvent to obtain a compound        represented by the following formula (u)

where R¹⁸, R², R³ and R⁴ are as defined above, or a salt of thecompound.

-   -   (2-7) The resulting compound of the formula (u) is reacted with        a compound represented by the following formula (m)        R¹⁸-A¹-H  (m)    -   where A¹ and R¹⁸ are as defined above,        in a solvent or under solventless conditions in the presence of        a base to carry out the formation of a salt, as appropriate,        thereby obtaining a compound represented by the following        formula (v)

where A¹, R¹⁸, X, R², R³ and R⁴ are as defined above, or apharmaceutically acceptable salt thereof.

-   -   (2-8) The resulting compound of the formula (v) is reacted with        a compound represented by the following formula (b)

where R⁶ is as defined above,

in a solvent or under solventless conditions in the presence of a base,whereby the compound of the present invention represented by thefollowing formula (w)

where A¹, R¹⁸, R², R³, R⁴ and R⁶ are as defined above, can be obtained.

-   -   (2-9) The resulting compound of the present invention,        represented by the formula (w), is reacted with a compound        represented by the following formula (j)        R⁵¹-L  (j)    -   where R⁵¹ and L are as defined above,        in a solvent or under solventless conditions in the presence of        a base, whereby another compound of the present invention        represented by the following formula (x)

where A¹, R¹⁸, R², R³, R⁴, R⁵¹ and R⁶ are as defined above, can beobtained.

Examples of the base used in the above reactions are alkali metal saltssuch as sodium carbonate, potassium carbonate, cesium carbonate, sodiumbicarbonate, potassium bicarbonate, sodium hydroxide, dimsyl sodium,sodium hydride, sodium amide, and tert-butyl potassium, amines such astriethylamine, diisopropylamine, pyrrolidine and piperidine, sodiumacetate, and potassium acetate.

Examples of the acid are inorganic acids (for example, hydrochloricacid, hydrobromic acid, hydroiodic acid, sulfuric acid and nitric acid),and organic acids (for example, trifluoroacetic acid, p-toluenesulfonicacid, and methanesulfonic acid).

As the oxidizing agent, there can be used, for example, organic peracidssuch as m-perchlorobenzoic acid, magnesium monoperphthalate hexahydrate,peracetic acid, and performic acid, inorganic and organic peroxides suchas hydrogen peroxide, urea hydrogen peroxide adduct/phthalic anhydride,tert-butyl hydroperoxide, and cumene hydroperoxide, sodium periodate,Oxone (registered trademark), N-bromosuccinimide, N-chlorosuccinimide,Chloramine-T, tert-butyl hypochlorite, iodobenzene diacetate, andbromo-1,4-diazabicyclo[2,2,2]octane addition complex.

As the reaction solvent, there can be used, for example, water, alcoholssuch as methanol, ethanol, isopropyl alcohol, and tert-butyl alcohol,ethers such as dioxane and tetrahydrofuran, and solvents inert toreactions, such as dimethylformamide, N,N′-dimethylacetamide,N,N′-dimethylpropyleneurea (DMPU), hexamethylphosphoramide (HMPA),dimethyl sulfoxide, pyridine, methylene chloride, chloroform, acetone,acetic acid, and benzene.

The reaction can be performed at atmospheric pressure, under pressurizedconditions, under microwave irradiation, etc. at an appropriatetemperature selected within the range of −78° C. to the boiling point ofthe solvent for the reaction.

When the compound of the present invention is to be used as apharmaceutical product, vehicles, bulking agents, pH regulators,solubilizers, etc. in common use are added to the compound of thepresent invention, the resulting blends are formed into tablets,granules, pills, capsules, powders, liquids and solutions, suspensions,injections, etc. by pharmaceutical manufacturing techniques in commonuse, and the resulting preparations can be administered orally or asinjections or as agents for topical application.

The compound of the present invention can be administered to an adultpatient in a daily dose of 1 to 1,000 mg given singly or as severaldivided portions. This dose can be increased or decreased, asappropriate, depending on the type of the disease, the age, body weightand symptoms of the patient, and so on.

Effects of the Invention

The compound of the present invention has been found to be a potentEdg-1(S1P₁) ligand, as demonstrated in the Test Examples to be describedlater.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention will be described in further detail by thefollowing Examples and Test Examples:

EXAMPLE 14-Chloro-N-[1-(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)butyl]benzenesulfonamide(Compound 128)

(1) Trimethylchlorosilane (12.4 ml) was added, at room temperature, to amethanol (37 ml) suspension of DL-norvaline (2.157 g), and the mixturewas stirred for 2 days at room temperature, and then heated under refluxfor 3 hours.

The reaction mixture was cooled to room temperature, and then thesolvent was distilled off under reduced pressure. The resulting lightyellow solid was dissolved in chloroform (37 ml), and triethylamine(10.3 ml) and 4-chlorobenzenesulfonyl chloride (3.886 g) were added at0° C., followed by stirring the mixture for 2 hours at room temperature.The reaction mixture was added to an aqueous solution (120 ml) ofhydrochloric acid (2 mols/liter), and the mixture was extracted withethyl acetate (200 ml), followed by washing the extract with a saturatedaqueous solution of sodium chloride (100 ml×2). The organic layer wasdried over anhydrous magnesium sulfate, and then the solvent wasdistilled off under reduced pressure to obtain2-{[(4-chlorophenyl)sulfonyl]amino}pentanoic acid methyl ester (4.592 g)as a light yellow oily substance.

¹H NMR (300 MHz, CDCl₃) δ ppm: 0.89 (t, J=7.3 Hz, 3H), 1.20-1.80 (m,4H), 3.52 (s, 3H), 3.87-3.98 (m, 1H), 5.11 (d, J=9.5 Hz, 1H), 7.47 (d,J=8.9 Hz, 2H), 7.77 (d, J=8.9 Hz, 2H)

(2) To a methanol (50 ml) solution of the2-{[(4-chlorophenyl)sulfonyl]amino}pentanoic acid methyl ester (4.590 g)obtained in Example 1-(1), hydrazine monohydrate (21.8 ml) was added atroom temperature, and the mixture was stirred for 14 hours at roomtemperature. From the reaction mixture, the solvent was distilled offunder reduced pressure, and water (150 ml) was added to the residue. Themixture was extracted with ethyl acetate (200 ml), and washed with asaturated aqueous solution of sodium chloride (100 ml×2).

The organic layer was dried over anhydrous magnesium sulfate, and thenthe solvent was distilled off under reduced pressure to obtain4-chloro-N-[1-(hydrazinocarbonyl)butyl]benzenesulfonamide (4.368 g).

Melting point: 120.0-120.5° C.

¹H NMR (300 MHz, DMSO-d₆) δ ppm: 0.74 (t, J=7.3 Hz, 3H), 0.98 1.52 (m,4H), 3.63 (t, J=7.2 Hz, 1H), 3.94 4.10 (m, 2H), 7.63 (d, J=8.9 Hz, 2H),7.75 (d, J=8.9 Hz, 2H), 8.08 (s, 1H), 9.10 (s, 1H)

(3) Methyl isothiocyanate (683 mg) was added, at room temperature, to anethanol (85 ml) solution of the4-chloro-N-[1-(hydrazinocarbonyl)butyl]benzenesulfonamide (2.596 g)obtained in Example 1-(2). The mixture was stirred for 30 minutes, andthen stirred for 2 hours under reflux conditions. The solvent wasdistilled off from the reaction mixture to obtain a solid. The solid waswashed with chloroform (100 ml), and then dried to obtain2-(2-{[(4-chlorophenyl)sulfonyl]amino}pentanoyl)-N-methylhydrazinecarbothioamide (2.868 g).

Melting point: 191.0-195.0° C.

¹H NMR (300 MHz, DMSO-d₆) δ ppm: 0.71 (t, J=7.3 Hz, 3H), 1.00 1.64 (m,4H), 2.88 (d, J=4.2 Hz, 3H), 3.56 3.75 (m, 1H), 7.26 7.46 (m, 1H), 7.66(d, J=8.7 Hz, 2H), 7.83 (d, J=8.7 Hz, 2H), 9.29 (s, 1H), 10.00 (s, 1H)

(4) An aqueous solution (8.5 ml) of sodium hydroxide (1 mol/liter) wasadded, at room temperature, to a mixed solution in methanol (9.5 ml) anddioxane (19 ml) of the2-(2-{[(4-chlorophenyl)sulfonyl]amino}pentanoyl)-N-methylhydrazinecarbothioamide (2.157 g) obtained in Example 1-(3). The mixture wasstirred for 30 minutes, and then stirred for 30 minutes at 85° C. Thesolvent was distilled off from the reaction mixture, and an aqueoussolution (20 ml) of hydrochloric acid (0.5 mol/liter) was added to theresidue. The mixture was extracted with ethyl acetate (100 ml), andwashed with a saturated aqueous solution (100 ml) of sodium chloride.

The organic layer was dried over anhydrous magnesium sulfate, and thenthe solvent was distilled off under reduced pressure to obtain Compound128 (2.177 g).

¹H NMR (300 MHz, CDCl₃) δ ppm: 0.89 (t, J=7.3 Hz, 3H), 1.20 1.95 (m,4H), 3.58 (s, 3H), 4.44 4.57 (m, 1H), 6.59 6.76 (m, 1H), 7.45 (d, J=8.5Hz, 2H), 7.69 (d, J=8.5 Hz, 2H), 11.41 (s, 1H)

EXAMPLE 2N-{1-[(5-allylthio)-4-methyl-4H-1,2,4-triazol-3-yl]butyl}-4-chlorobenzenesulfonamide(Compound 125)

Diisopropylamine (0.407 ml) and allyl bromide (0.218 ml) were added, atroom temperature, to a tetrahydrofuran (9.7 ml) solution of the4-chloro-N-[1-(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)butyl]benzenesulfonamide(Compound 128) (698 mg) obtained in Example 1-(4), and the mixture wasstirred overnight at room temperature. The solvent was distilled offfrom the reaction mixture under reduced pressure. The resulting residuewas dissolved in ethyl acetate (100 ml), and the solution was washedsequentially with an aqueous solution (50 ml) of hydrochloric acid (1mol/liter) and a saturated aqueous solution (100 ml) of sodium chloride.The organic layer was dried over anhydrous magnesium sulfate, and thenthe solvent was distilled off under reduced pressure. The residue wasrecrystallized from a solvent mixture of hexane (20 ml) and ethylacetate (15 ml) for purification, thereby obtaining Compound 125 (590mg).

Melting point: 161.5-162.0° C.

¹H NMR (300 MHz, CDCl₃) δ ppm: 0.86 (t, J=7.3 Hz, 3H), 1.15 1.35 (m,2H), 1.65 1.96 (m, 2H), 3.39 (s, 3H), 3.73 3.80 (m, 2H), 4.37 4.49 (m,1H), 5.07 5.27 (m, 2H), 5.85 6.01 (m, 2H), 7.40 (d, J=8.9 Hz, 2H), 7.70(d, J=8.9 Hz, 2H)

EXAMPLE 3N-{(1R)-1-[5-(benzylthio)-4-ethyl-4H-1,2,4-triazol-3-yl]ethyl}-4-chloro-benzenesulfonamide(Compound 5)

Mesyl chloride (25.8 mg) and triethylamine (0.055 ml) were added to achloroform (0.9 ml) solution of benzyl alcohol (16.2 mg), and themixture was stirred for 3 hours at room temperature. The reactionmixture was eluted by NH-type silica gel (Chromatorex, Fuji SilysiaChemical Ltd.) column chromatography using tetrahydrofuran as a solventto obtain methanesulfonic acid benzyl ester. To a tetrahydrofuran (0.9ml) solution of the methanesulfonic acid benzyl ester,4-chloro-N-[(1R)-1-(4-ethyl-5-mercapto-4H-1,2,4-triazol-3-yl)ethyl]benzenesulfonamide(Compound 90) (17.3 mg) obtained by performing the same procedure as inExample 1 using the corresponding raw materials, and potassiumt-butoxide (8.4 mg) were added, followed by stirring the mixture for 20hours at 40° C. PSA (polymer supported amine) (0.15 ml) was added to thereaction mixture, and the resulting mixture was stirred for 4 hours atroom temperature. The reaction mixture was eluted with ethyl acetate andtetrahydrofuran, and the solvents were distilled off. The resultingresidue was eluted by NH-type silica gel column chromatography usingtetrahydrofuran as a solvent, and the eluate was purified by silica gelcolumn chromatography to obtain Compound 5 (2.3 mg).

¹H NMR (200 MHz, DMSO-d₆) δ ppm: 1.10 (t, J=7.1 Hz, 3H), 1.25 (d, J=6.8Hz, 3H), 3.62 3.96 (m, 2H), 4.36 (s, 2H), 4.55 4.78 (m, 1H), 7.15 7.47(m, 5H), 7.64 (d, J=8.6 Hz, 2H), 7.77 (d, J=8.6 Hz, 2H), 8.52 (d, J=8.6Hz, 1H)

EXAMPLE 44-Chloro-N-{(1R)-1-[4-ethyl-5-(methylsulfinyl)-4H-1,2,4-triazol-3-yl]ethyl}benzenesulfonamide(Compound 180, Compound 181)

To a chloroform (18 ml) solution of4-chloro-N-{(1R)-1-[4-ethyl-5-(methylthio)-4H-1,2,4-triazol-3-yl]ethyl}benzenesulfonamide(Compound 1) (329 mg) obtained by performing the same procedure as inExamples 1 and 2 using the corresponding raw materials,m-perchlorobenzoic acid (157 mg) was added under ice-cooling conditions.The mixture was stirred for 30 minutes at 0° C., and then stirredovernight at room temperature. The reaction solution was washed with asaturated aqueous solution (20 ml) of sodium bicarbonate. The organiclayer was dried over anhydrous magnesium sulfate, and then the solventwas distilled off under reduced pressure. The resulting residue waseluted by silica gel flash column chromatography using a solvent mixtureof acetone and ethyl acetate. The eluate was developed twice bypreparative TLC (Merck, analytical TLC plate, 20×20 cm, Silicagel60F₂₅₄×4 plates) using ethyl acetate as a solvent. Then, the developedsubstances were eluted using a 5% methanol/chloroform mixed solution toobtain Compound 180 (14 mg) of low polarity and Compound 181 (21 mg) ofhigh polarity (Compound 180 and Compound 181: diastereomers).

Compound 180 of low polarity: ¹H NMR (300 MHz, CDCl₃) δ ppm: 1.47 (t,J=7.2 Hz, 3H), 1.54 (d, J=6.8 Hz, 3H), 3.26 (s, 3H), 4.18 4.46 (m, 2H),4.63 4.78 (m, 1H), 5.95 (d, J=9.6 Hz, 1H), 7.45 (d, J=8.5 Hz, 2H), 7.70(d, J=8.5 Hz, 2H)

Compound 181 of high polarity: ¹H NMR (300 MHz, CDCl₃) δ ppm: 1.47 (t,J=7.3 Hz, 3H), 1.55 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.18 4.49 (m, 2H),4.63 4.80 (m, 1H), 6.00 (d, J=9.3 Hz, 1H), 7.46 (d, J=8.8 Hz, 2H), 7.72(d, J=8.8 Hz, 2H)

Compound 54-Chloro-N-{(1R)-1-[4-ethyl-5-(methylsulfonyl)-4H-1,2,4-triazol-3-yl]ethyl}benzenesulfonamide(Compound 182)

To a chloroform (30 ml) solution of4-chloro-N-{(1R)-1-[4-ethyl-5-(methylthio)-4H-1,2,4-triazol-3-yl]ethyl}benzenesulfonamide(Compound 1) (520 mg) obtained by performing the same procedure as inExamples 1 and 2 using the corresponding raw materials,m-perchlorobenzoic acid (746 mg) was added under ice-cooling conditions,followed by stirring the mixture for 1 hour at 0° C. A saturated aqueoussolution (100 ml) of sodium bicarbonate was added to the reactionmixture, and the resulting mixture was extracted with chloroform (50ml). The organic layer was dried over anhydrous magnesium sulfate, andthen the solvent was distilled off under reduced pressure. The resultingresidue was purified by silica gel flash column chromatography using asolvent mixture of ethyl acetate and chloroform to obtain Compound 182(481 mg).

¹H NMR (300 MHz, CDCl₃) δ ppm: 1.46 (t, J=7.3 Hz, 3H), 1.54 1.60 (m,3H), 3.49 (s, 3H), 4.25 4.40 (m, 2H), 4.65 4.78 (m, 1H), 5.44 (d, J=9.8Hz, 1H), 7.45 (d, J=8.9 Hz, 2H), 7.68 (d, J=8.9 Hz, 2H)

EXAMPLE 6N-{(1R)-1-[5-(allylthio)-4-ethyl-4H-1,2,4-triazol-3-yl]ethyl}-4-chloro-N-methylbenzenesulfonamide(Compound 99)

To a dimethylformamide (2 ml) solution ofN-{(1R)-1-(5-allylthio)-4-ethyl-4H-1,2,4-triazol-3-yl}ethyl)-4-chlorobenzenesulfonamide(Compound 3) (200 mg) obtained by performing the same procedure as inExamples 1 and 2 using the corresponding raw materials, potassiumcarbonate (120 mg) and methyl iodide (0.040 ml) were added at roomtemperature, followed by stirring the mixture for 3 hours at roomtemperature. Ethyl acetate was added to the reaction mixture, and theresulting mixture was washed sequentially with a 1 mol/liter aqueoussolution of hydrochloric acid and a saturated aqueous solution of sodiumchloride. The organic layer was dried over anhydrous magnesium sulfate,and then the solvent was distilled off under reduced pressure. Theresulting residue was eluted by silica gel flash column chromatographyusing a solvent mixture of ethyl acetate and hexane. Then, the eluatewas recrystallized using a solvent mixture of ethyl acetate and hexanefor purification, whereby Compound 98 (112 mg) was obtained.

Melting point: 142.0-143.0° C.

¹H NMR (200 MHz, DMSO-d₆) δ ppm: 1.13 (d, J=6.8 Hz, 3H), 1.27 (t, J=7.1Hz, 3H), 2.56 (s, 3H), 3.82 (d, J=7.1 Hz, 2H), 3.90 4.25 (m, 2H), 5.045.27 (m, 2H), 5.43 (q, J=6.8 Hz, 1H), 5.82 6.06 (m, 1H), 7.74 (d, J=8.8Hz, 2H), 7.90 (d, J=8.8 Hz, 2H)

EXAMPLE 74-Chloro-N-[(1R)-1-(4-ethyl-5-propoxy-4H-1,2,4-triazol-3-yl)ethyl]benzenesulfonamide(Compound 183)

Sodium hydride (12 mg) was added, while cooled with ice, to adimethylformamide (1.2 ml) solution of the4-chloro-N-{(1R)-1-[4-ethyl-5-(methylsulfonyl)-4H-1,2,4-triazol-3-yl]ethyl}benzenesulfonamide(Compound 182) (47 mg) obtained in Example 5 and n-propanol (0.027 ml).The mixture was stirred for 30 minutes at room temperature, and thenstirred for 2 hours at 100° C. After the reaction mixture was cooled toroom temperature, it was added to a saturated aqueous solution (5 ml) ofammonium chloride. The mixture was extracted with ethyl acetate (20ml×2) and washed with a saturated aqueous solution (20 ml) of sodiumchloride. The organic layer was dried over anhydrous magnesium sulfate,and then the solvent was distilled off under reduced pressure. Theresulting residue was purified by silica gel flash column chromatographyusing a solvent mixture of methanol and chloroform to obtain Compound183 (35 mg).

¹H NMR (300 MHz, CDCl₃) δ ppm: 1.02 (t, J=7.5 Hz, 3H), 1.24 (t, J=7.2Hz, 3H), 1.47 (d, J=6.8 Hz, 3H), 1.75 1.91 (m, 2H), 3.68 3.80 (m, 2H),4.37 (t, J=6.5 Hz, 2H), 4.45 4.58 (m, 1H), 5.60 (bs, 1H), 7.45 (d, J=8.6Hz, 2H), 7.77 (d, J=8.6 Hz, 2H)

EXAMPLE 8 (1R)-1-(4-Ethyl-5-methoxy-4H-[1,2,4]-triazol-3-yl)ethylamine(Compound 519)

(1) Hydrazine monohydrate (30 ml) was added to a methanol (180 ml)solution of N-(t-butoxycarbonyl)-D-alanine methyl ester (41.8 g), andthe mixture was stirred for 12 hours at room temperature. The reactionmixture was concentrated, and the resulting crude crystals were washedwith a solvent mixture of hexane and ethyl acetate (1:1, 300 ml). Then,the washed crystals were dried to obtain(R)-(1-hydrazinocarbonyl-2-ethyl)carbamic acid t-butyl ester as acolorless powder (32.6 g).

¹H NMR (300 MHz, DMDO-d₆) δ ppm: 1.14 (d, J=7.2 Hz, 3H), 1.37 (s, 9H),3.30-4.09 (m, 3H), 6.70-6.90 (m, 1H), 8.96 (br s, 1H)

(2) Ethyl isothiocyanate (14.6 ml) was added to an EtOH (152 ml)solution of the (R)-(1-hydrazinocarbonyl-2-ethyl)carbamic acid t-butylester (30.8 g) obtained in Example 8-(1), and the mixture was heated for2 hours under reflux. After the reaction mixture was cooled to roomtemperature, crystals precipitated were filtered. The filtrate wasconcentrated, and the resulting residue was purified by silica gelchromatography using a solvent mixture of ethyl acetate and chloroform,whereby(R)-2-(N-(t-butoxycarbonyl)amino)propionyl)-N-ethylhydrazinecarbothioamidewas obtained as a colorless amorphous substance (43.2 g).

¹H NMR (300 MHz, DMSO-d₆) δ ppm: 0.98-1.28 (m, 6H), 1.40 (s, 9H),3.25-3.65 (m, 2H), 3.77-3.95 (m, 1H), 7.20-7.39 (m, 1H), 7.45-7.60 (m,1H), 9.25 (s, 1H), 10.00 (s, 1H)

(3) An aqueous solution (218 ml) of sodium hydroxide (1 mol/liter) wasadded to a mixed solution, in methanol (120 ml) and dioxane (240 ml), ofthe(R)-2-(N-(t-butoxycarbonyl)amino)propionyl)-N-ethylhydrazinecarbothioamide(42.1 g) obtained in Example 8-(2), followed by heating the mixture for3 hours under reflux. The reaction mixture was concentrated, and anaqueous solution (100 ml) of hydrochloric acid (2 mols/liter) was added.The mixture was extracted with an ethyl acetate-CHCl₃-MeOH mixedsolution (10:10:1, 500 ml), and the organic layer was dried overanhydrous magnesium sulfate. Then, the solvent was distilled off underreduced pressure, and the resulting residue was washed with a solventmixture of hexane and ethyl acetate (1:1, 300 ml), followed by drying,to obtain[(R)-1-(4-ethyl-5-mercapto-4H-[1,2,4]triazol-3-yl)ethyl]-carbamic acidt-butyl ester as a white solid (29.22 g).

¹H NMR (300 MHz, DMSO-d₆) δ ppm: 1.21 (t, J=7.1 Hz, 3H), 1.30-1.50 (m,3H), 1.39 (s, 9H), 3.82-4.05 (m, 2H), 4.72-4.88 (m, 1H), 7.58 (d, J=8.5Hz, 1H), 13.60 (br s, 1H)

(4) Diisopropylamine (17.4 ml) and iodomethane (7.7 ml) were added to atetrahydrofuran (200 ml) solution of the[(R)-1-(4-ethyl-5-mercapto-4H-[1,2,4]triazol-3-yl)ethyl]-carbamic acidt-butyl ester (28.12 g) obtained in Example 8-(3). The mixture wasstirred for 1 hour at room temperature, and then precipitated crystalswere filtered. The filtrate was concentrated, and the resulting crudecrystals were washed with a hexane-ethyl acetate solvent mixture (3:1,200 ml), followed by drying, to obtain[(R)-1-(4-ethyl-5-methylsulfanyl-4H-[1,2,4]triazol-3-yl)ethyl]-carbamicacid t-butyl ester as a white powder (29.5 g).

¹H NMR (300 MHz, DMSO-d₆) δ ppm: 1.21 (t, J=7.0 Hz, 3H), 1.38 (s, 9H),1.45 (t, J=7.0 Hz, 3H), 2.62 (s, 3H), 3.80-4.00 (m, 2H), 4.85-4.92 (m,1H), 7.52 (d, J=8.5 Hz, 1H)

(5) To a chloroform (293 ml) solution of the[(R)-1-(4-ethyl-5-methylsulfanyl-4H-[1,2,4]triazol-3-yl)ethyl]-carbamicacid t-butyl ester (21.0 g) obtained in Example 8-(4),m-perchlorobenzoic acid (43.0 g) was added in four portions while beingcooled with ice. The mixture was stirred for 3 hours at roomtemperature, and then stirred for 1 hour at 40° C. To the reactionmixture, Na₂S₂O₃ (12.9 g) and an aqueous solution (300 ml) of sodiumhydroxide (1 mol/liter) were added. The organic layer was separated, andwashed with a saturated aqueous solution of sodium chloride. The organiclayer was dried over anhydrous magnesium sulfate, and then the solventwas distilled off under reduced pressure. The resulting residue waspurified by silica gel flash column chromatography using a solventmixture of hexane and ethyl acetate. Then, the purified substance wasrecrystallized using hexane and chloroform to obtain[(R)-1-(4-ethyl-5-methanesulfonyl-4H-[1,2,4]triazol-3-yl)ethyl]-carbamicacid t-butyl ester as a white powder (17.2 g).

¹H NMR (300 MHz, CDCl₃) δ ppm: 1.44 (s, 9H), 1.49 (t, J=7.1 Hz, 3H),1.67 (t, J=6.8 Hz, 3H), 3.53 (s, 3H), 4.25-4.59 (m, 2H), 4.92-5.20 (m,2H)

(6) Trifluoroacetic acid (121 ml) was added to the[(R)-1-(4-ethyl-5-methanesulfonyl-4H-[1,2,4]triazol-3-yl)ethyl]-carbamicacid t-butyl ester (100.0 g) obtained in Example 8-(5), and the mixturewas stirred for 2 hours at room temperature. The reaction mixture wasconcentrated under reduced pressure to obtain(R)-1-(4-ethyl-5-methanesulfonyl-4H-[1,2,4]triazol-3-yl)ethylaminetrifluoroacetate as a white powder (103.8 g).

¹H NMR (300 MHz, DMSO-d₆) δ ppm: 1.37 (t, J=7.2 Hz, 3H), 1.59 (t, J=6.8Hz, 3H), 3.65 (s, 3H), 4.21-4.50 (m, 2H), 4.72-4.90 (m, 1H), 8.69 (br s,3H)

(7) NaOMe (18 ml, 2.0N, MeOH solution) was added to the(R)-1-(4-ethyl-5-methanesulfonyl-4H-[1,2,4]triazol-3-yl)ethylaminetrifluoroacetate (3.0 g) obtained in Example 8-(6), and the mixture washeated for 1 hour under reflux. The reaction mixture was cooled to roomtemperature, and Et₂O (100 ml) was added. After the mixture was cooledto 0° C., precipitated crystals were filtered. The filtrate wasconcentrated, and the resulting crude product was purified by NH silicagel chromatography using a solvent mixture of Et₂O and MeOH to obtainthe captioned compound (Compound 519) as a colorless oily substance(1.55 g).

¹H NMR (300 MHz, CDCl₃) δ ppm: 1.32 (t, J=7.2 Hz, 3H), 1.54 (t, J=6.7Hz, 3H), 3.78-3.95 (m, 2H), 4.02-4.20 (m, 1H), 4.13 (s, 3H)

EXAMPLE 9[(1R)-1-(4-Ethyl-5-methoxy-4H-[1,2,4]triazol-3-yl)ethyl]benzenesulfonamide(Compound 376)

A tetrahydrofuran (0.9 ml) solution of benzenesulfonyl chloride (31 mg)was added, at room temperature, to the compound (20 mg) obtained inExample 8-(7). Then, triethylamine (0.040 ml) was added, and the mixturewas stirred for 3 hours at room temperature. The reaction mixture waseluted by NH-type silica gel column chromatography using tetrahydrofuranas a solvent, and then the eluate was concentrated to obtain thecaptioned compound (36.5 mg).

¹H NMR (200 MHz, CDCl₃) δ ppm: 1.24 (t, J=7.1 Hz, 3H), 1.41 (t, J=7.0Hz, 3H), 3.79 (q, J=7.1 Hz, 3H), 4.09 (s, 3H), 4.40-4.67 (m, 1H),6.20-6.60 (m, 1H), 7.40-7.62 (m, 3H), 7.80-7.98 (m, 2H)

EXAMPLE 10

Using the same methods as the methods used in Examples 1 to 9, saltswere formed, as appropriate, to obtain the compounds shown in the tablesoffered below. As Compounds 89, 104, 136 and 137, those purchased fromBionet were used.

The compounds obtained in the above-described Examples 1 to 9 are alsoshown in Table 1 along with the other compounds.

TEST EXAMPLE 1 Cell System Binding Test

Using a human Edg-1(S1P₁) gene transferred HEK-293 cell strain (showinga binding of Kd=6.4±2.1 nM, Bmax=160±94 fmol/10⁵ cells to [³H]-S1P),which had been obtained by a method complying with the method describedin the literature (Science. 1998, 279:1552), the Edg-1(S1P₁) bindinginhibiting effect of the compound of the present invention wasinvestigated in accordance with the method described in the literature.Cells (1×10⁵ cells/well) obtained as described above were seeded inpoly-L-lysine-coated 96-well plates (Corning Incorporated), and thenincubated in a 5% carbon dioxide gas incubator for 12 hours at 37° C.with the use of an MEM medium (Invitrogen Corporation) containing 100U/mL of penicillin, 100 μg/mL of streptomycin, a 1% MEM nonessentialamino acid solution, and 10% FCS. The cultured cells were washed twicewith a buffer (20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 15 mM NaF, 2 mMdeoxypyridoxine, 4 mg/mL fatty acid-free BSA), and was then treated with100 μL of the buffer incorporating [³H]-S1P (produced by ARC, endconcentration 10 nM) and a DMSO solution of the test compound (endconcentration of the compound: 10⁻⁵ M, end concentration of DMSO: 0.1%)for 1 hour at 4° C. After the cells were washed twice with the buffer,they were solubilized with 100 μL of Opti Phase Supermix (produced byPerkin-Elmer), and measured for radioactivity by means of Micro Beta(produced by Perkin-Elmer). Based on the radioactivity, the amount (A)of binding of [³H]-S1P upon the addition of the compound was calculated.

The same procedure was performed in the absence of the test compound,and the amount (B) of binding of [³H]-S1P was calculated. Moreover, thesame procedure was performed in the absence of the test compound withthe use of HEK-293 cells, to which the Edg-1(S1P₁) gene had not beentransferred, and the background amount (C) of binding of [³H]-S1P wascalculated.

The Edg-1(S1P₁) binding inhibition rate of the compound, calculated fromthe following equation, is shown in Table 1.Inhibition rate(%)=[1−(A−C)/(B−C)]×100

TEST EXAMPLE 2 Membrane System Binding Test

Using a human Edg-1(S1P₁) gene transferred HEK-293 cell strain membranefraction, the Edg-1(S1P₁) binding inhibiting effect of the compound ofthe present invention was investigated in accordance with the methoddescribed in the literature (Science. 2002, 296:346) (showing a bindingof Kd=0.15 nM, Bmax=2.5 fmol/μg to [³³P]-S1P). The membrane fraction wasobtained by treating the cells with a solubilizing buffer (1 mMTris/HCl, pH 7.2) for 10 minutes on ice, centrifuging the system(1000×g, 5 min) to remove insoluble fractions, and then centrifuging thesystem (40000×g, 30 min, 4° C.). The resulting membrane fraction wasdissolved in a binding buffer (20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 15mM NaF, 2 mM deoxypyridoxine, 4 mg/mL fatty acid-free BSA), and then[³³P]-S1P (produced by ARC, end concentration 0.1 nM) and a DMSOsolution of the test compound (end concentration of the compound: 10⁻⁵M, end concentration of DMSO: 0.1%) were added, followed by stirring themixture and subsequently treating it for 1 hour at 30° C. Using aharvester, the membrane fraction was harvested onto unifilter-96GF/Cfilter (produced by Perkin-Elmer). Then, the filter with the membranefraction was washed 4 times with the binding buffer, and the filter wasdried. To the filter, 25 μL Microscint 0 (produced by Perkin-Elmer) wasadded, and the assay system was measured for radioactivity by means ofTop Count NXT (Packard). Based on the radioactivity, the amount (A) ofbinding of [³³P]-S1P to the membrane fraction upon addition of thecompound was calculated.

The same procedure was performed in the absence of the test compound,and the amount (B) of binding of [³³P]-S1P was calculated. Moreover, thesame procedure was performed in the absence of the test compound withthe use of HEK-293 cells, to which the Edg-1(S1P₁) gene had not beentransferred, and the background amount (C) of binding of [³³P]-S1P wascalculated.

The Edg-1(S1P₁) binding inhibition rate of the compound, calculated fromthe following equation, is shown in

TABLE 1 Inhibition rate (%) = [1 − (A − C) / (B − C)] × 100 MeltingCompound point No. CHEMISTRY (° C.) ¹H NMR Compound  1

176.0- 177.0 Compound  2

129.5- 130.5 Compound  3

110.0- 113.0 Compound  4

116.0- 117.0 Compound  5

(200 MHz, DMSO-d6) δ ppm: 1.10 (t, J = 7.1 Hz., 3H), 1.25 (d, J = 6.8Hz, 3H), 3.62-3.96 (m, 2H), 4.36 (s, 2H), 4.55-4.78 (m. 1H), 7.15-7.47(m, 5H), 7.64 (d, J = 8.6 Hz, 2H), 7.77 (d, J = 8.6 Hz, 2H), 8.02 (d, J= 8.6 Hz, 1H) Compound  6

Compound  7

Compound  8

Compound  9

Compound  10

Compound  11

Compound  12

Compound  13

Compound  14

Compound  15

Compound  16

Compound  17

Compound  18

Compound  19

Compound  20

Compound  21

Compound  22

Compound  23

Compound  24

Compound  25

Compound  26

Compound  27

Compound  28

Compound  29

Compound  30

Compound  31

Compound  32

Compound  33

Compound  34

Compound  35

Compound  36

Compound  37

Compound  38

Compound  39

Compound  40

Compound  41

Compound  42

Compound  43

Compound  44

Compound  45

Compound  46

Compound  47

Compound  48

Compound  49

Compound  50

Compound  51

Compound  52

Compound  53

Compound  54

Compound  55

Compound  56

Compound  57

Compound  58

Compound  59

Compound  60

Compound  61

Compound  62

Compound  63

Compound  64

Compound  65

Compound  66

Compound  67

Compound  68

Compound  69

Compound  70

Compound  71

Compound  72

Compound  73

Compound  74

Compound  75

Compound  76

Compound  77

Compound  78

Compound  79

Compound  80

Compound  81

Compound  82

Compound  83

Compound  84

Compound  85

Compound  86

Compound  87

Compound  88

Compound  89

Compound  90

169.5- 172.5 Compound  91

164.5- 165.0 Compound  92

128.5- 130.0 Compound  93

(300 MHz, DMSO-d6) δ ppm: 1.23 (d, J = 6.8 Hz, 3H), 3.37 (s, 3H),4.55-4.69 (m, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H),8.53 (d, J = 7.9 Hz, 1H), 13.61 (s, 1H) Compound  94

Compound  95

117.5- 118.0 Compound  96

(300 MHz, DMSO-d6) δ ppm: 0.88 (t, J = 7.4 Hz, 3H), 1.18 (d, J = 6.7 Hz,3H), 1.54-1.84 (m, 2H), 3.72-3.99 (m, 2H), 4.56-4.70 (m, 1H), 7.68 (d, J= 8.7 Hz, 2H), 7.80 (d, J = 8.7 Hz, 2H), 8.57 (d, J = 8.7 Hz, 1H), 13.63(s, 1H) Compound  97

172.5- 173.45 Compound  98

(300 MHz, CDCl3) δ ppm: 1.49 (d, J = 6.8 Hz, 3H), 1.56-1.69 (m, 6H),4.75-5.05 (m, 2H), 6.57- 6.67 (m, 1H), 7.48 (d, J = 8.6 Hz, 2H), 7.77(d, J = 8.8 Hz, 2H), 11.74 (bs, 1H) Compound  99

142.0- 143.0 Compound 100

221.0- 222.0 Compound 101

(300 MHz, DMSO-d6) δ ppm: 1.45 (s, 6H), 3.50 (s, 3H) 7.62 (d, J = 8.9Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 8.66 (s, 1H), 13.59 (s, 1H) Compound102

115.5- 116.0 Compound 103

(300 MHz, DMSO-d6) δ ppm: 3.36 (s, 3H), 4.13 (s, 2H) 7.66 (d, J = 8.9Hz, 2H), 7.76 (d, J = 8.9 Hz, 2H), 8.53 (bs, 1H), 13.58 (s, 1H) Compound104

Compound 105

155.5- 157.5 Compound 106

144.5- 145.5 Compound 107

(300 MHz, DMSO-d6) δ ppm: 0.75 (t, J = 7.3 Hz, 3H), 1.59-1.86 (m, 2H),3.26 ? 3.40 (m, 3H), 4.27-4.39 (m, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.70(d, J = 8.9 Hz, 2H), 8.65 (bs, 1H), 13.58 (bs, 1H) Compound 108

(300 MHz, CDCl3) δ ppm: 0.90 (t, J = 7.3 Hz, 3H), 1.76-1.98 (m, 2H),3.58 (s, 3H), 4.40-4.49 (m, 1H), 6.75 (bs, 1H), 7.44-7.50 (m, 2H),7.68-7.76 (m, 2H), 11.89 (bs, 1H) Compound 109

155.5- 156.5 Compound 110

Compound 111

(300 MHz, DMSO-d6) δ ppm: 0.74 (t, J = 7.3 Hz, 3H), 1.18 (t, J = 7.2 Hz,3H), 1.56-1.84 (m, 2H), 3.78 ? 4.08 (m, 2H), 4.26-4.40 (m, 1H), 7.62 (d,J = 8.9 Hz, 2H), 7.71 (d, J = 8.9 Hz, 2H), 8.60-8.72 (m, 1H), 13.59 (s,1H) Compound 112

Compound 113

141.5- 142.0 Compound 114

(300 MHz, DMSO-d6) δ ppm: 0.74 (t, J = 7.3 Hz, 3H), 0.83 (t, J = 7.4 Hz,3H), 1.46-1.92 (m, 4H), 3.68-3.85 (m, 2H), 4.30-4.47 (m, 1H), 5.03-5.30(m, 2H), 5.81-6.00 (m, 1H), 7.48-7.72 (m, 4H), 8.63 (d, J = 8.2 Hz, 1H)Compound 115

(300 MHz, DMSO-d6) δ ppm: 0.75 (t, J = 7.3 Hz, 3H), 0.86 (t, J = 7.4 Hz,3H), 1.52-1.84 (m, 4H), 3.66 ? 3.94 (m, 2H), 4.26-4.37 (m, 1H), 7.62 (d,J = 8.9 Hz, 2H), 7.71 (d, J = 8.9 Hz, 2H), 8.66 (d, J = 7.9 Hz, 1H),13.60 (s, 1H) Compound 116

(300 MHz, CDCl3) δ ppm: 0.92 (t, J = 7.3 Hz, 3H), 1.02 (t, J = 7.4 Hz,3H), 1.75-1.91 (m, 4H), 8.93-4.09 (m, 2H), 4.40-4.50 (m, 1H), 7.20 (br,1H), 7.41-7.52 (m, 2H), 7.70-7.77 (m, 2H), 12.14 (bs, 1H) Compound 117

161.5- 164.0 Compound 118

(300 MHz, CDCl3) δ ppm: 0.96 (t, J = 7.3 Hz, 3H), 1.55-1.68 (m, 6H),1.74-1.90 (m, 2H), 4.54-4.64 (m, 1H), 4.92 (bs, 1H), 6.79 (bs, 1H),7.42-7.51 (m, 2H), 7.70-7.77 (m, 2H), 11.74 (bs, 1H) Compound 119

163.0- 164.0 Compound 120

(300 MHz, DMSO-d6) δ ppm: 0.74 (t, J = 7.3 Hz, 3H), 1.44-1.98 (m, 10H),4.36-4.51 (m, 1H), 4.63-4.74 (m, 1H), 7.60-7.65 (m, 2H), 7.69-7.75 (m,2H), 8.50-8.74 (m, 1H), 13.52 (bs, 1H) Compound 121

172.0- 173.0 Compound 122

(300 MHz, DMSO-d6) δ ppm: 0.43 (t, J = 7.3 Hz, 3H), 1.32-1.54 (m, 2H),3.97-4.16 (m, 1H), 5.04 (d, J = 16.1 Hz, 1H), 5.84 (d, J = 16.1 Hz, 1H),7.09-7.45 (m, 5H), 7.47-7.66 (m, 4H), 8.70 (d, J = 7.9 Hz, 1H), 13.78(s, 1H) Compound 123

172.5- 173.5 Compound 124

(300 MHz, DMSO-d6) δ ppm: 0.74 (t, J = 7.2 Hz, 3H), 1.04-1.88 (m, 12H)4.32-4.52 (m, 1H) 7.48-7.93 (m, 4H) 8.62 (d, J = 7.6 Hz, 1H) 13.56 (bs,1H) Compound 125

161.5- 162.0 (300 MHz, CDCl3) δ ppm: 0.86 (t, J = 7.3 Hz, 3H), 1.15-1.35(m, 2H), 1.65-1.96 (m, 2H), 3.39 (s, 3H), 3.73-3.80 (m, 2H), 4.87-4.49(m, 1H), 5.07-5.27 (m, 2H), 5.85-6.01 (m, 2H), 7.40 (d, J = 8.9 Hz, 2H),7.70 (d, J = 8.9 Hz, 2H) Compound 126

166.0- 164.0 Compound 127

155.0- 156.0 Compound 128

(300 MHz, CDCl3) δ ppm: 0.89 (t, J = 7.3 Hz, 3H), 1.20-1.95 (m, 4H),3.58 (s, 3H), 4.44-4.57 (m, 1H), 6.59-6.76 (m, 1H), 7.45 (d, J = 8.5 Hz,2H), 7.69 (d, J = 8.5 Hz, 2H), 11.41 (s, 1H) Compound 129

150.5- 151.5 Compound 130

(200 MHz, CDCl3) δ ppm: 0.89 (d, J = 6.8 Hz, 3H), 1.03 (d, J = 6.6 Hz,3H), 2.18-2.46 (m, 1H), 3.61 (s, 3H), 4.04-4.30 (m, 1H), 7.30-7.74 (m,5H), 12.23 (bs, 1H) Compound 131

171.5- 173.5 Compound 132

(300 MHz, DMSO-d6) δ ppm: 3.38 (s, 3H), 5.83 (bs, 1H), 7.14-7.25 (m,5H), 7.39-7.46 (m, 2H), 7.52-7.59 (m, 2H), 9.14 (bs, 1H), 13.66 (bs, 1H)Compound 133

126.0- 128.0 Compound 134

122.5- 125.0 Compound 135

172.0- 174.0 Compound 136

Compound 137

Compound 138

109.0- 110.0 Compound 139

138.5- 139.5 Compound 140

(300 MHz, CDCl3) δ ppm: 1.12 (t, J = 7.2 Hz, 3H), 3.10-3.24 (m, 2H),3.70-3.82 (m, 1H), 3.89-4.01 (m, 1H), 4.69-4.72 (m, 1H), 6.62 (bs, 1H),6.97-7.03 (m, 2H), 7.19-7.25 (m, 3H), 7.38-7.48 (m, 2H), 7.57-7.68 (m,2H), 11.40 (bs, 1H) Compound 141

Compound 142

Compound 143

Compound 144

(300 MHz, CDCl3) δ ppm: 1.37-1.56 (m, 6H), 2.94-3.24 (m, 2H), 4.74-4.89(m, 2H), 6.10- 6.45 (m, 1H), 6.96-7.06 (m, 2H), 7.12-7.28 (m, 3H),7.29-7.43 (m, 2H), 7.54-7.65 (m, 2H), 11.00-11.45 (m, 1H) Compound 145

112.0- 112.5 Compound 146

(300 MHz, CDCl3) δ ppm: 0.92 (t, J = 7.1 Hz, 3H), 1.18-1.43 (m, 2H),1.45-1.91 (m, 2H), 3.10-3.30 (m, 2H), 3.59-4.01 (m, 2H), 4.57-4.80 (m,1H), 6.93-7.65 (m, 10H), 12.11 (bs, 1H) Compound 147

117.0- 117.5 Compound 148

Compound 149

Compound 150

(300 MHz, CDCl3) δ ppm: 0.60-1.00 (m, 3H), 1.15-2.40 (m, 5H), 3.00-3.30(m, 2H), 4.81-4.94 (m, 1H), 6.95-7.63 (m, 10H), 11.98 (bs, 1H) Compound151

Compound 152

(300 MHz, DMSO-d6) δ ppm: 2.84-3.17 (m, 2H), 3.14 (s, 3H), 3.28-3.56 (m,2H), 3.86-4.19 (m, 2H), 4.65-4.77 (m, 1H), 7.04-7.28 (m, 5H), 7.43-7.50(m, 4H), 8.85 (bs, 1H), 13.69 (bs, 1H) Compound 153

(300 MHz, DMSO-d6) δ ppm: 2.81-4.49 (m, 16H), 4.60-4.85 (m, 1H),4.93-5.27 (m, 2H), 5.78-6.01 (m, 1H), 7.03-7.27 (m, 5H), 7.42-7.58 (m,2H), 7.58-7.77 (m, 2H), 8.97 (d, J = 8.2 Hz, 1H), 11.85 (bs, 1H)Compound 154

(300 MHz, CDCl3) δ ppm: 2.77-3.34 (m, 4H), 3.52-3.92 (m, 4H), 3.90-4.42(m, 4H), 4.62-4.87 (m, 2H), 5.04-5.35 (m, 1H), 6.91-7.25 (m, 7H),7.40-7.54 (m, 2H), 8.71 (d, J = 6.2 Hz, 1H), 11.30 (bs, 1H), 12.69 (bs,1H) Compound 155

186.5- 187.5 Compound 156

(300 MHz, CDCl3) δ ppm: 1.24-2.45 (m, 6H), 2.68-3.04 (m, 3H), 3.17-3.32(m, 1H), 3.50-4.02 (m, 4H), 4.39-4.91 (m, 2H), 5.13-5.35 (m, 1H),7.00-7.24 (m, 7H), 7.44-7.53 (m, 2H), 8.92 (d, J = 6.5 Hz, 1H), 11.12(bs, 1H), 11.81 (bs, 1H) Compound 157

Compound 158

Compound 159

(300 MHz, DMSO-d6) δ ppm: 2.82-3.18 (m, 2H), 3.50-3.76 (m, 2H),4.57-4.84 (m, 3H), 4.99-5.26 (m, 2H), 5.72-5.98 (m, 1H), 6.95-7.27 (m,5H), 7.81-7.73 (m, 4H), 8.81 (d, J = 8.6 Hz, 1H), 13.59 (bs, 1H)Compound 160

(300 MHz, DMSO-d6) δ ppm: 2.78-3.12 (m, 2H), 4.48-4.91 (m, 3H),7.09-7.22 (m, 5H), 7.45-7.59 (m, 4H), 8.85 (d, J = 8.4 Hz, 1H), 13.43(bs, 1H) 13.75 (s, 1H) Compound 161

126.0- 128.0 Compound 162

149.5- 150.0 Compound 163

(300 MHz, CDCl3) δ ppm: 2.27-3.06 (m, 2H), 4.35-4.70 (m, 1H), 5.29 (bs,2H), 6.57-7.53 (m, 15H), 11.88 (bs, 1H) Compound 164

168.0- 173.0 Compound 165

(300 MHz, CDCl3) δ ppm: 1.45-2.10 (m, 6H), 2.20-2.00 (m, 2H), 3.10-3.25(m, 2H), 4.55-4.70 (m, 1H), 4.80-4.90 (m, 1H), 6.88-7.69 (m, 10H), 11.78(bs, 1H) Compound 166

114.0- 115.5 Compound 167

(300 MHz, DMSO-d6) δ ppm: 2.77-3.07 (m, 2H), 3.84-4.02 (m, 1H),6.69-7.60 (m, 14H), 8.94 (bs, 1H), 13.91 (bs, 1H) Compound 168

132.0- 133.0 Compound 169

162.5- 165.0 Compound 170

179.0- 181.0 Compound 171

143.0- 144.0 Compound 172

205.0- 206.0 Compound 173

(300 MHz, DMSO-d6) δ ppm: 0.86-1.35 (m, 4H), 3.25-3.43 (m, 3H),7.49-7.70 (m, 4H), 9.03 (bs, 1H), 13.47 (bs, 1H) Compound 174

211.0- 216.0 Compound 175

(300 MHz, DMSO-d6) δ ppm: 1.42-1.91 (m, 2H), 2.05-2.62 (m, 4H),3.10-3.40 (m, 3H), 7.28-7.73 (m, 4H), 8.70-8.95 (m, 1H), 13.57 (bs, 1H)Compound 176

225.0- 226.0 Compound 177

(300 MHz, CDCl3) δ ppm: 1.00-2.50 (m, 8H), 3.49 (s, 3H), 7.35-7.85 (m,4H) Compound 178

196.0- 197.0 Compound 179

(300 MHz, CDCl3) δ ppm: 1.12-2.22 (m, 10H), 3.61 (s, 3H), 7.33-7.94 (m,5H), 10.41 (bs, 1H) Compound 180

(300 MHz, CDCl3) δ ppm: 1.47 (t, J = 7.2 Hz, 3H), 1.54 (d, J = 6.8 Hz,3H), 3.26 (s, 3H), 4.18-4.46 (m, 2H), 4.63-4.78 (m, 1H), 5.95 (d, J =9.6 Hz, 1H), 7.42-7.48 (m, 2H), 7.73-7.80 (m, 2H) Compound 181

(300 MHz, CDCl3) δ ppm: 1.47 (t, J = 7.3 Hz, 3H), 1.55 (d, J = 6.8 Hz,3H), 3.24 (s, 3H), 4.18-4.49 (m, 2H), 4.63-4.80 (m, 1H), 6.00 (d, J =9.3 Hz, 1H), 7.42-7.49 (m, 2H), 7.67-7.75 (m, 2H) Compound 182

129.0- 130.0 (300 MHz, CDCl3) δ ppm: 1.46 (t, J = 7.3 Hz, 3H), 1.54-1.60(m, 3H), 3.49 (s, 3H), 4.25-4.40 (m, 2H), 4.65-4.78 (m, 1H), 5.44 (d, J= 9.8 Hz, 1H), 7.41-7.48 (m, 2H), 7.65-7.71 (m, 2H) Compound 183

150.5- 151.5 Compound 184

154.0- 155.5 Compound 185

148.0- 150.0 Compound 186

151.0- 152.0 Compound 187

142.0- 146.0 Compound 188

 86.0-  90.0 Compound 189

(300 MHz, CDCl₃) δ ppm: 1.24 (t, J = 7.3 Hz, 3H), 1.32-1.54 (m, 6H),1.46 (d, J = 6.8 Hz, 3H), 1.74-1.86 (m, 2H), 2.15-2.29 (m, 2H), (m, 2H),2.21 (s, 6H), 3.70-3.80 (m, 2H), 4.40 (t, J = 6.6 Hz, 2H), 4.47-4.57 (m,1H), 7.40-7.49 (m, 2H), 7.74-7.81 (m, 2H) Compound 190

(300 MHz, CDCl₃) δ ppm: 1.28 (t, J = 7.3 Hz, 3H), 1.45 (d, J = 7.0 Hz,3H), 1.55-2.15 (m, 1H), 3.75-3.90 (m, 2H), 3.92-4.02 (m, 2H), 4.48-4.63(m, 3H), 6.04 (d, J = 9.2 Hz, 1H), 7.43-7.51 (m, 2H), 7.75-7.85 (m, 2H)Compound 191

124.5- 126.0 Compound 192

(300 MHz, CDCl₃) δ ppm: 0.88 (t, J = 6.6 Hz, 3H), 1.07-1.93 (m, 31H),1.46 (d, J = 6.8 Hz, 3H), 3.67-3.82 (m, 2H), 4.39 (t, J = 6.6 Hz, 2H),4.43-4.60 (m, 1H), 5.64-6.13 (m, 1H), 7.38-7.50 (m, 2H), 7.72-7.84 (m,2H) Compound 193

145.0- 146.0 Compound 194

182.0- 164.0 Compound 195

119.5- 120.5 Compound 196

121.0- 123.0 Compound 197

116.5- 118.0 Compound 198

Compound 199

Compound 200

162.0- 163.0 Compound 201

Compound 202

Compound 203

Compound 204

Compound 205

Compound 206

141.5- 142.5 Compound 207

Compound 208

150.0- 150.5 Compound 209

189.0- 189.5° C. Compound 210

Compound 211

Compound 212

Compound 213

Compound 214

Compound 215

151.0- 151.5 Compound 216

Compound 217

Compound 218

Compound 219

Compound 220

133.5- 134.5 Compound 221

Compound 222

112.0- 113.0 Compound 223

154.5- 156.5 Compound 224

Compound 225

Compound 226

Compound 227

Compound 228

Compound 229

Compound 230

 99.0- 100.0 Compound 231

Compound 232

Compound 233

196.0- 196.5 Compound 234

Compound 235

Compound 236

Compound 237

Compound 238

170.5- 171.0 Compound 239

Compound 240

Compound 241

Compound 242

Compound 243

Compound 244

Compound 245

180.0- 180.5 Compound 246

Compound 247

Compound 248

178.5- 179.0 Compound 249

163.5- 164.5 Compound 250

Compound 251

Compound 252

Compound 253

Compound 254

Compound 255

Compound 256

Compound 257

Compound 258

Compound 259

Compound 260

Compound 261

Compound 262

Compound 263

(300 MHz, CDCl3) d ppm 1.26 (t, J = 7.2 Hz, 3H) 2.92-3.03 (m, 1H)3.05-3.17 (m, 1H) 3.25- 3.53 (m, 2H) 4.04 (s, 3H) 4.42-4.53 (m, 1H) 5.93(s, 1H) 6.64-6.73 (m, 2H) 6.76-6.83 (m, 2H) 7.34-7.41 (m, 2H) 7.62-7.69(m, 2H) 7.70 (s, 1H) Compound 264

Compound 265

Compound 266

Compound 267

140.0- 140.5 Compound 268

124.0- 125.0 Compound 269

117.5- 118.0 Compound 270

Compound 271

Compound 272

Compound 273

Compound 274

130.0- 131.0 Compound 275

132.0- 133.0 Compound 276

Compound 277

Compound 278

Compound 279

Compound 280

Compound 281

118.5- 119.5 Compound 282

Compound 283

Compound 284

Compound 285

Compound 286

Compound 287

156.5- 157.0 Compound 288

Compound 289

Compound 290

Compound 291

Compound 292

Compound 293

Compound 294

Compound 295

Compound 296

Compound 297

Compound 298

Compound 299

Compound 300

Compound 301

Compound 302

Compound 303

Compound 304

Compound 305

Compound 306

Compound 307

Compound 308

Compound 309

Compound 310

127.5- 128.0 Compound 311

138.0- 139.0 Compound 312

Compound 313

186.0- 186.5 Compound 314

156.0- 156.5 Compound 315

157.0- 157.5 Compound 316

Compound 317

157.0- 158.0 Compound 318

Compound 319

168.0- 168.5 Compound 320

Compound 321

137.5- 138.0 Compound 322

Compound 323

Compound 324

Compound 325

Compound 326

Compound 327

Compound 328

Compound 329

Compound 330

Compound 331

Compound 332

Compound 333

Compound 334

Compound 335

Compound 336

Compound 337

Compound 338

Compound 339

Compound 340

Compound 341

159.0- 160.0 Compound 342

Compound 343

Compound 344

Compound 345

Compound 346

Compound 347

Compound 348

Compound 349

Compound 350

Compound 351

Compound 352

Compound 353

Compound 354

Compound 355

Compound 356

Compound 357

Compound 358

Compound 359

Compound 360

Compound 361

Compound 362

Compound 363

Compound 364

Compound 365

Compound 366

Compound 367

Compound 368

Compound 369

178.0- 178.5 Compound 370

Compound 371

Compound 372

175.5- 176.0 Compound 373

Compound 374

Compound 375

150.5- 151.5 Compound 376

161.0- 162.0 Compound 377

199.0- 200.0 Compound 378

168.0- 169.0 Compound 379

156.5- 157.5 Compound 380

(300 MHz, CDCl3) δ ppm 1.18-1.97 (m, 12H), 3.59-4.00 (m, 3H), 4.33-4.69(m, 5H), 7.17 (br s, 1H), 7.36-7.53 (m, 2H), 7.65-7.89 (m, 2H) Compound381

162.5- 163.5 Compound 382

176.0- 177.0 Compound 383

(300 MHz, CDCl3) δ ppm: 1.14 (t, J = 7.1 Hz, 3H), 1.24 (t, J = 7.2 Hz,3H), 1.33 (t, J = 7.2 Hz, 3H), 1.44 (d, J = 6.8 Hz, 3H), 3.27 (q, J =7.2 Hz, 2H), 3.40 (q, J = 7.2 Hz, 2H), 3.90 (q, J = 7.1 Hz, 2H),4.47-4.62 (m, 1H), 5.02 (d, J = 14.5 Hz, 1H), 5.12 (d, J = 14.5 Hz, 1H),5.89 (d, J = 8.8 Hz, 1H), 7.40-7.53 (m, 2H), 7.73-7.89 (m, 2H) Compound384

139.0- 140.0 Compound 385

169.0- 170.0 Compound 386

(300 MHz, CDCl3) δ ppm: 0.76 (t, J = 7.2 Hz, 3H), 0.99 (t, J = 7.5 Hz,3H), 1.64-1.87 (m, 2H), 3.11-3.43 (m, 4H), 4.27-4.36 (m, 2H), 4.40-4.52(m, 1H), 6.01-6.21 (m, 1H), 6.96-7.05 (m, 2H), 7.14-7.23 (m, 3H),7.31-7.40 (m, 2H), 7.58-7.68 (m, 2H) Compound 387

200.0- 201.0 Compound 388

199.0- 200.0 Compound 389

149.0- 150.0 Compound 390

147.5- 148.5 Compound 391

151.0- 152.0 Compound 392

158.0- 160.0 Compound 393

110.5- 113.0 Compound 394

101.5- 103.5 Compound 395

128.5- 130.0 Compound 396

167.5- 168.0 Compound 397

155.5- 156.5 Compound 398

130.0- 132.0 Compound 399

156.0- 156.5 Compound 400

109.0- 111.0 Compound 401

149.5- 150.5 Compound 402

164.5- 166.0 Compound 403

184.5- 185.5 Compound 404

140.0- 140.5 Compound 405

172.0- 172.5 Compound 406

184.5- 185.5 Compound 407

167.0- 168.0 Compound 408

110.5- 111.5 Compound 409

183.0- 184.0 Compound 410

128.5- 129.5 Compound 411

135.0- 136.0 Compound 412

159.5- 160.0 Compound 413

175.5- 176.5 Compound 414

111.0- 112.0 Compound 415

113.0- 114.0 Compound 416

101.0- 102.0 Compound 417

125.0- 125.5 Compound 418

181.5- 182.5 Compound 419

199.5- 200.5 Compound 420

138.0- 139.0 Compound 421

181.0- 182.0 Compound 422

158.0- 159.0 Compound 423

134.5- 136.5 Compound 424

153.0- 154.0 Compound 425

140.0- 142.0 Compound 426

149.0- 151.0 Compound 427

174.0- 175.0 Compound 428

163.5- 165.0 Compound 429

114.5- 115.5 Compound 430

139.0- 140.0 Compound 431

148.0- 149.0 Compound 432

146.5- 147.5 Compound 433

169.5- 170.0 Compound 434

165.5- 166.0 Compound 435

204.5- 205.5 Compound 436

172.5- 173.5 Compound 437

145.5- 146.0 Compound 438

151.0- 152.5 Compound 439

129.5- 130.5 Compound 440

167.0- 168.0 Compound 441

143.0- 144.0 Compound 442

152.0- 153.0 Compound 443

169.0- 170.0 Compound 444

216.0- 217.0 Compound 445

133.0- 136.0 Compound 446

135.5- 137.0 Compound 447

125.5- 126.5 Compound 448

152.5- 153.0 Compound 449

161.0- 165.5 Compound 450

175.0- 175.5 Compound 451

145.5- 155.5 Compound 452

151.5- 152.5 Compound 453

181.0- 181.5 Compound 454

180.0- 181.0 Compound 455

196.5- 197.0 Compound 456

152.5- 153.0 Compound 457

150.0- 150.5 Compound 458

204.5- 205.0 Compound 459

150.5- 151.0 Compound 460

159.5- 160.5 Compound 461

185.0- 187.0 Compound 462

150.0- 150.5 Compound 463

189.5- 190.0 Compound 464

188.0- 189.0 Compound 465

172.0- 175.0 Compound 466

117.5- 118.0 Compound 467

190.0- 191.0 Compound 468

123.5- 124.0 Compound 469

120.0- 121.0 Compound 470

145.5- 147.0 Compound 471

147.0- 149.0 Compound 472

159.0- 161.0 Compound 473

191.0- 192.0 Compound 474

197.5- 198.0 Compound 475

206.5- 207.5 Compound 476

205.5- 206.5 Compound 477

151.5- 153.5 Compound 478

183.0- 184.0 Compound 479

168.5- 169.0 Compound 480

158.0- 158.5 Compound 481

110.0- 111.0 Compound 482

160.0- 163.0 Compound 483

 79.0-  81.0 Compound 484

 78.0-  81.0 Compound 485

157.5- 158.5 Compound 486

145.0- 146.0 Compound 487

173.0- 174.0 Compound 488

137.0- 138.0 Compound 489

127.0- 128.0 Compound 490

155.0- 156.0 Compound 491

94.0- 95.0 Compound 492

150.0- 151.0 Compound 493

109.0- 110.0 Compound 494

169.0- 170.0 Compound 495

139.5- 140.5 Compound 496

139.0- 140.0 Compound 497

 93.0-  94.0 Compound 498

(300 MHz, CDCl3) δ ppm: 1.28 (t, J = 7.2 Hz, 3H), 1.47 (d, J = 6.8 Hz,3H), 2.69 (s, 3H), 3.37-3.83 (m, 2H), 4.46-4.58 (m, 1H), 5.43 (brd, J =8.9 Hz, 1H), 7.21-7.29 (m, 1H), 7.57 (d, J = 1.1, 7.9 Hz, 1H), 7.92 (d,J = 1.1, 8.1 Hz, 1H) Compound 499

127.0- 128.0 Compound 500

143.5- 144.5 Compound 501

145.5- 146.5 Compound 502

170.0- 171.0 Compound 503

123.0- 124.0 Compound 504

103.0- 104.0 Compound 505

138.0- 139.0 Compound 506

168.0- 169.0 Compound 507

141.0- 143.0 Compound 508

152.0- 153.0 Compound 509

123.0- 124.5 Compound 510

177.0- 178.0 Compound 511

166.0- 167.0 Compound 512

109.0- 110.0 Compound 513

162.5- 163.5 Compound 514

119.0- 119.5 Compound 515

138.5- 139.5 Compound 516

109.5- 110.0 Compound 517

126.0- 127.0 Compound 518

215.0- 218.0 Compound 519

(300 MHz, CDCl3) δ ppm: 1.32 (t, J = 7.2 Hz, 3H), 1.54 (d, J = 6.8 Hz,3H), 3.78-3.98 (m, 2H), 4.03-4.20 (m, 1H), 4.13 (s, 3H) Compound 520

(300 MHz, CDCl3) δ ppm: 1.31 (t, J = 7.2 Hz, 3H), 1.44 (d, J = 7.1 Hz,3H), 1.54 (d, J = 6.7 Hz, 3H), 1.65 (bs, 2H), 3.80-3.97 (m, 2H), 4.08(q, J = 6.7 Hz, 1H), 4.51 (q, J = 7.2 Hz, 2H) Compound 521

(300 MHz, CDCl3) δ ppm: 1.30 (t, J = 7.2 Hz, 3H), 1.41 (d, J = 6.1 Hz,6H), 1.58 (d, J = 6.7 Hz, 3H), 3.79-3.91 (m, 2H), 4.10-4.22 (m, 1H),5.07-5.29 (m, 1H) Compound 522

(300 MHz, CDCl3) δ ppm: 1.35 (t, J = 7.2 Hz, 3H), 1.57 (d, J = 6.7 Hz,3H), 3.87-4.07 (m, 2H), 4.11 (q, J = 6.7, 1H), 4.84 (q, J = 8.1, 2H)Compound 523

194.5- 195.5 Compound 524

240.5- 242.5 Compound 525

196.5- 198.5 Compound 526

232.5- 234.5 Compound 527

177.0- 179.0 Compound 528

174.0- 175.5 Compound 529

184.0- 185.0 Compound 530

185.5- 190.0 Compound 531

204.0- 205.0 Compound 532

104.0- 107.0 Compound 533

188.0- 189.0 Compound 534

192.0- 193.0 Compound 535

148.5- 150.0 Compound 536

160.0- 162.0 Compound 537

176.0- 178.0 Compound 538

120.5- 123 Compound 539

(200 MHz, CDCl3) δ ppm: 1.18 (t, J = 7.3 Hz, 3H), 3.06 (dd, J = 13.4,8.6 Hz, 1H), 3.33 (dd, J = 13.4, 5.7 Hz, 1H), 3.55-3.90 (m, 2H), 4.07(dd, J = 8.6, 5.7 Hz, 1H), 4.13 (s, 3H), 7.10-7.38 (m, 5H) Compound 540

187.5- 188.0 Compound 541

141.5- 142.0 Compound 542

178.0- 180.0 Compound 543

183.0- 184.0 Compound 544

118.5- 120.0 Compound 545

185.0- 189.0 Compound 546

164.5- 165.5 Compound 547

181.0- 185.0 Compound 548

177.0- 179.5 Compound 549

206.0- 207.5 Compound 550

143.0- 144.5 Compound 551

181.5- 183.0 Compound 552

191.0- 196.0 Compound 553

229.0- 230.0 Compound 554

236.0- 237.0 Compound 555

(600 MHz, CDCl3) δ ppm: 0.90 (d, J = 6.9 Hz, 3H), 1.27 (d, J = 7.8 Hz,3H), 3.08-3.28 (m, 2H), 3.87-4.01 (m, 1H), 4.09 (s, 3H), 4.54-4.64 (m,1H), 6.97-7.05 (m, 2H), 7.14-7.21 (m, 3H), 7.48 (d, J = 8.3 Hz, 1H),7.56-7.67 (m, 1H), 7.75-7.83 (m, 1H) Compound 556

(600 MHz, DMSO-d6) δ ppm: 1.10 (t, J = 7.1 Hz, 3H), 1.83-1.95 (m, 2H),2.29-2.43 (m, 4H), 2.39 (t, J = 7.1 Hz, 2H), 2.94 (dd, J = 13.3, 7.3 Hz,1H), 3.16 (dd, J = 13.3, 6.9 Hz, 1H), 3.50- 3.62 (m, 4H), 3.65-3.83 (m,2H), 3.97-4.06 (m, 1H), 4.35 (t, J = 6.6 Hz, 2H), 7.12-7.30 (m, 5H)Compound 557

(600 MHz, CDCl3) δ ppm: 0.30-0.36 (m, 2H), 0.55-0.61 (m, 2H), 1.17 (t, J= 7.3 Hz, 3H), 1.24-1.34 (m, 1H), 3.02 (dd, J = 13.3, 8.7 Hz, 1H), 3.29(dd, J = 13.3, 5.7 Hz, 1H), 3.63-3.82 (m, 2H), 4.02 (dd, J = 8.7, 5.7Hz, 1H), 4.21- 4.25 (m, 2H), 7.14-7.30 (m, 5H) Compound 558

(200 MHz, CDCl3) δ ppm: 1.17 (t, J = 7.0 Hz, 3H), 2.96-3.41 (m, 2H),3.53-4.24 (m, 3H), 5.47 (s, 2H), 7.07-7.58 (m, 10H) Compound 559

(600 MHz, DMSO-d6) δ ppm: 1.13 (t, J = 7.3 Hz, 3H), 3.00 (dd, J = 13.5,7.6 Hz, 1H), 3.22 (dd, J = 13.5, 6.6 Hz, 1H), 3.67-3.89 (m, 2H), 3.99(s, 3H), 4.08-4.10 (m, 1H), 7.27-7.39 (m, 3H), 7.41-7.49 (m, 2H),7.53-7.60 (m, 2H), 7.60-7.70 (m, 2H) Compound 560

(600 MHz, DMSO-d6) δ ppm: 1.11 (t, J = 7.1 Hz, 3H), 2.94 (dd, J = 13.4,7.6 Hz, 1H), 3.15 (dd, J = 13.4, 6.9 Hz, 1H), 3.67-3.85 (m, 2H),3.97-4.03 (m, 1H), 3.99 (s, 3H), 6.99-7.12 (m, 2H), 7.18-7.30 (m, 2H)Compound 561

(600 MHz, DMSO-d6) δ ppm: 1.14 (t, J = 7.3 Hz, 3H), 2.95 (dd, J = 13.6,7.8 Hz, 1H), 3.17 (dd, J = 13.6, 6.4 Hz, 1H), 3.71-3.88 (m, 2H),3.97-4.04 (m, 1H), 3.99 (s, 3H), 7.03-7.11 (m, 1H), 7.26-7.37 (m, 2H)Compound 562

(600 MHz, DMSO-d6) δ ppm: 1.14 (t, J = 7.1 Hz, 3H), 3.00 (dd, J = 13.6,7.8 Hz, 1H), 3.18 (dd, J = 13.6, 6.4 Hz, 1H), 3.71-3.79 (m, 1H),3.80-3.89 (m, 1H), 3.99 (s, 3H), 4.04-4.08 (m, 1H), 7.03-7.16 (m, 2H),7.21-7.28 (m, 1H), 7.27-7.33 (m, 1H) Compound 563

(600 MHz, CDCl3) δ ppm: 1.21 (t, J = 7.1 Hz, 3H), 3.07 (dd, J = 13.4,8.7 Hz, 1H), 3.35 (dd, J = 13.4, 5.7 Hz, 1H), 3.67-3.86 (m, 2H),4.02-4.09 (m, 1H), 4.13 (s, 3H), 6.90-6.96 (m, 2H), 6.97-7.01 (m, 1H),7.23-7.30 (m, 1H) Compound 564

(600 MHz, CDCl3) δ ppm: 1.24 (t, J = 7.1 Hz, 3H), 3.06 (dd, J = 13.7,8.3 Hz, 1H), 3.37 (dd, J = 13.7, 5.7 Hz, 1H), 3.71-3.80 (m, 1H),3.81-3.89 (m, 1H), 4.01-4.07 (m, 1H), 4.14 (s, 3H), 6.66-6.71 (m, 1H),6.74-6.80 (m, 2H) Compound 565

(600 MHz, CDCl3) δ ppm: 3.06 (dd, J = 13.4 Hz, 1H), 3.18 (s, 3H), 3.24(dd, J = 13.4, 6.0 Hz, 1H), 4.05-4.14 (m, 1H), 4.11 (s, 3H), 7.13-7.33(m, 5H) Compound 566

(600 MHz, CDCl3) δ ppm: 0.83 (t, J = 7.6 Hz, 3H), 1.47-1.80 (m, 2H),3.07 (dd, J = 13.5, 8.3 Hz, 1H), 3.31 (dd, J = 13.5, 6.0 Hz, 1H),3.44-3.53 (m, 1H), 3.60-3.68 (m, 1H), 4.01 (dd, J = 8.3, 6.0 Hz, 1H),4.11 (s, 3H), 7.14-7.33 (m, 5H) Compound 567

(600 MHz, CDCl3) δ ppm: 1.25 (d, J = 6.9 Hz, 3H), 1.39 (d, J = 6.9 Hz,3H), 3.04 (dd, J = 13.6, 8.9 Hz, 1H), 3.28 (dd, J = 13.6, 5.5 Hz, 1H),4.11 (s, 3H), 4.21-4.29 (m, 1H), 7.15-7.38 (m, 5H) Compound 568

(600 MHz, CDCl3) δ ppm: 0.65-0.75 (m, 1H), 0.86-0.98 (m, 3H), 2.33-2.42(m, 1H), 3.10 (dd, J = 13.3, 7.8 Hz, 1H), 3.24 (dd, J = 13.3, 6.9 Hz,1H), 4.09 (s, 3H), 4.21-4.29 (m, 1H), 7.11-7.32 (m, 5H) Inhibition rate(%) = [1 − (A − C) / (B − C)] × 100 Cell system Membrane system bindingtest binding test Compound % inhibition % inhibition No. ESI MS (M + H)⁺ESI MS (M − H)− APCI MS (M − H)− (10 μM) (10 μM) Compound  1 361 35989.8 72.3 Compound  2 389 387 88.5 100.6 Compound  3 387 385 86.1 89.1Compound  4 385 383 86.8 101.4 Compound  5 437 435 97.2 81.2 Compound  6513 94.3 99.0 Compound  7 462 460 460 88.5 74.6 Compound  8 429 427 83.985.6 Compound  9 415 413 413 90.1 86.7 Compound  10 401 399 399 85.654.3 Compound  11 455 85.5 45.1 Compound  12 509 87.8 85.9 Compound  13429 429 80.8 43.6 Compound  14 401 399 87.0 69.6 Compound  15 457 45591.0 79.4 Compound  16 405 403 403 92.1 64.4 Compound  17 413 85.5 90.6Compound  18 489 84.8 100.4 Compound  19 485 483 82.5 100.3 Compound  20445 443 84.3 74.3 Compound  21 401 399 82.2 74.8 Compound  22 449 82.196.9 Compound  23 467 465 465 84.4 95.0 Compound  24 419 417 417 82.660.6 Compound  25 443 441 441 81.5 77.8 Compound  26 421 84.0 61.1Compound  27 399 397 86.9 76.0 Compound  28 415 93.1 82.8 Compound  29401 93.0 95.9 Compound  30 459 91.9 100.5 Compound  31 417 415 415 90.290.0 Compound  32 451 449 449 89.1 99.1 Compound  33 401 91.7 90.0Compound  34 413 91.5 76.4 Compound  35 471 469 469 91.9 87.7 Compound 36 475 89.5 103.9 Compound  37 479 92.7 92.8 Compound  38 463 461 91.581.0 Compound  39 463 93.8 86.7 Compound  40 513 511 87.0 46.1 Compound 41 449 87.3 97.3 Compound  42 469 85.4 98.8 Compound  43 505 503 90.5102.4 Compound  44 469 93.0 99.6 Compound  45 469 91.7 91.3 Compound  46503 90.4 99.5 Compound  47 465 463 92.5 99.2 Compound  48 487 485 93.0101.3 Compound  49 415 94.8 93.9 Compound  50 507 505 95.3 96.2 Compound 51 463 461 91.2 93.0 Compound  52 495 493 93.6 89.1 Compound  53 375373 90.8 89.3 Compound  54 389 387 88.7 105.4 Compound  55 401 399 94.3104.0 Compound  56 462 480 87.1 91.0 Compound  57 411 92.6 100.5Compound  58 495 91.9 98.1 Compound  59 451 93.2 96.9 Compound  60 48390.3 97.2 Compound  61 449 95.0 98.9 Compound  62 450 92.9 90.6 Compound 63 436 93.7 99.7 Compound  64 436 91.3 86.5 Compound  65 458 456 45683.3 83.1 Compound  66 474 472 472 84.0 90.6 Compound  67 430 73.8 42.2Compound  68 466 464 464 93.0 97.9 Compound  69 452 450 450 89.5 92.7Compound  70 442 88.4 98.0 Compound  71 480 478 89.7 104.4 Compound  72534 532 89.8 95.8 Compound  73 457 93.9 98.4 Compound  74 495 493 49393.6 109.3 Compound  75 494 492 92.7 99.4 Compound  76 470 97.3 101.0Compound  77 494 89.4 96.4 Compound  78 458 456 456 83.0 96.5 Compound 79 470 84.7 94.9 Compound  80 515 513 86.2 87.5 Compound  81 482 48087.6 110.4 Compound  82 492 84.7 90.4 Compound  83 402 85.6 99.5Compound  84 441 439 87.9 100.4 Compound  85 488 90.4 106.0 Compound  86509 507 507 93.4 110.3 Compound  87 431 429 429 82.7 84.7 Compound  88431 429 429 87.6 97.1 Compound  89 89.3 Compound  90 345 60.6 48.8Compound  91 371 72.9 47.4 Compound  92 371 88.3 Compound  93 331Compound  94 331 Compound  95 401 399 94.0 60.2 Compound  96 359Compound  97 399 88.9 52.5 Compound  98 381 359 Compound  99 401 75.857.4 Compound 100 385 Compound 101 345 Compound 102 357 Compound 103 317Compound 104 99.5 42.1 Compound 105 385 71.5 Compound 106 387 385 86.952.5 Compound 107 345 Compound 108 345 Compound 109 399 93.0 100.2Compound 110 90.1 88.0 Compound 111 359 Compound 112 359 Compound 113413 84.0 46.3 Compound 114 90.6 74.5 Compound 115 373 Compound 116 375373 Compound 117 415 413 93.6 83.8 Compound 118 375 373 Compound 119 439Compound 120 399 Compound 121 461 Compound 122 421 Compound 123 453Compound 124 Compound 125 401 399 69.0 52.4 Compound 126 449 77.0Compound 127 465 463 63.6 Compound 128 361 359 Compound 129 399 Compound130 361 359 Compound 131 433 Compound 132 393 Compound 133 449 447Compound 134 449 447 88.8 84.8 Compound 135 86.7 96.9 Compound 136 102.794.7 Compound 137 99.0 57.1 Compound 138 463 461 94.7 102.1 Compound 13991.0 107.2 Compound 140 421 Compound 141 477 475 94.8 79.5 Compound 142435 Compound 143 477 475 96.0 88.7 Compound 144 435 Compound 145 46.0Compound 146 451 449 Compound 147 489 75.2 Compound 148 451 449 Compound149 491 489 63.4 Compound 150 451 449 Compound 151 493 491 41.6 Compound152 451 Compound 153 546 26.8 Compound 154 508 506 Compound 155 545 544Compound 156 506 504 Compound 157 548 548 Compound 158 508 506 Compound159 491 Compound 160 451 Compound 161 499 497 Compound 162 523 Compound163 Compound 164 501 40.4 Compound 165 463 461 Compound 166 Compound 167469 Compound 168 433 431 Compound 169 447 445 67.5 72.9 Compound 170 495493 Compound 171 367 365 Compound 172 383 Compound 173 343 Compound 174397 Compound 175 Compound 176 413 411 Compound 177 Compound 178 427 425Compound 179 Compound 180 377 375 48.9 Compound 181 377 375 Compound 182391 53.7 Compound 183 373 371 373 89.2 97.7 Compound 184 371 373 44.4Compound 185 345 343 87.4 86.6 Compound 186 359 357 89.3 94.5 Compound187 400 82.9 46.4 Compound 188 416 414 82.0 46.3 Compound 189 458 456105.3 107.2 Compound 190 375 373 91.1 41.3 Compound 191 389 387 97.188.3 Compound 192 555 553 75.5 105.3 Compound 193 345 343 108.0 64.4Compound 194 345 343 85.6 Compound 195 369 367 103.1 91.2 Compound 196353 351 105.7 88.5 Compound 197 329 327 Compound 198 366 366 92.5 46.7Compound 199 353 351 351 93.0 54.9 Compound 200 387 97.4 93.3 Compound201 365 92.6 45.3 Compound 202 289 96.6 60.3 Compound 203 471 97.9 88.3Compound 204 387 97.8 45.4 Compound 205 381 99.6 47.4 Compound 206 387102.7 86.2 Compound 207 365 365 95.8 43.5 Compound 208 393 99.9 93.0Compound 209 388 91.4 103.7 Compound 210 309 91.8 46.6 Compound 211 40093.9 46.9 Compound 212 334 92.4 45.6 Compound 213 334 96.2 66.1 Compound214 413 96.8 59.3 Compound 215 357 98.3 94.4 Compound 216 393 97.2 63.7Compound 217 383 97.4 62.3 Compound 218 402 402 101.1 40.2 Compound 219377 95.9 Compound 220 383 97.2 98.0 Compound 221 369 89.9 56.1 Compound222 337 337 92.9 71.8 Compound 223 327 95.5 70.4 Compound 224 277 275275 92.2 54.5 Compound 225 351 94.0 Compound 226 339 92.3 42.4 Compound227 249 247 92.6 52.0 Compound 228 387 93.9 Compound 229 359 102.5 61.1Compound 230 359 102.6 102.5 Compound 231 354 96.6 40.3 Compound 232 354Compound 233 354 99.8 93.2 Compound 234 368 388 90.9 Compound 235 387110.6 63.8 Compound 236 345 98.9 Compound 237 399 399 95.4 52.5 Compound238 435 99.1 79.1 Compound 239 277 275 275 92.7 Compound 240 362 360 36093.4 70.3 Compound 241 335 101.5 80.5 Compound 242 317 315 315 100.149.9 Compound 243 323 101.6 66.0 Compound 244 323 92.3 Compound 245 37796.8 87.7 Compound 246 323 98.1 61.8 Compound 247 393 95.3 52.0 Compound248 323 99.5 83.3 Compound 249 377 100.6 86.3 Compound 250 455 455 88.742.9 Compound 251 422 102.1 105.5 Compound 252 427 102.9 100.0 Compound253 361 83.4 Compound 254 330 328 328 84.6 Compound 255 373 373 96.348.3 Compound 256 357 357 95.6 Compound 257 371 371 95.7 58.1 Compound258 341 89.8 Compound 259 367 86.8 Compound 260 377 89.4 46.9 Compound261 385 94.5 56.7 Compound 262 351 96.5 68.8 Compound 263 Compound 264353 95.8 42.7 Compound 265 445 98.2 69.5 Compound 266 377 97.0 83.0Compound 267 357 99.9 89.4 Compound 268 361 98.7 88.6 Compound 269 33996.3 74.5 Compound 270 423 94.8 61.3 Compound 271 379 89.6 Compound 272465 465 101.7 94.3 Compound 273 353 94.3 68.4 Compound 274 377 102.2103.5 Compound 275 393 99.4 71.9 Compound 276 393 88.9 Compound 277 33499.7 51.4 Compound 278 401 70.9 Compound 279 345 100.8 Compound 280 32791.0 Compound 281 75.5 Compound 282 351 351 92.7 48.1 Compound 283 43573.9 Compound 284 379 88.0 41.5 Compound 285 365 363 363 97.1 63.9Compound 286 345 97.5 57.4 Compound 287 345 100.3 80.1 Compound 288 405103.0 54.9 Compound 289 379 101.7 63.6 Compound 290 423 423 99.9 86.0Compound 291 379 97.8 77.6 Compound 292 391 96.7 51.4 Compound 293 35731.8 Compound 294 341 341 64.5 Compound 295 391 66.1 Compound 296 391Compound 297 413 23.8 Compound 298 345 85.7 Compound 299 327 94.5 44.4Compound 300 373 95.0 Compound 301 395 78.3 Compound 302 383 98.7 57.7Compound 303 465 97.7 56.1 Compound 304 368 79.8 Compound 305 357 86.5Compound 306 465 94.5 62.8 Compound 307 352 96.2 68.0 Compound 308 33795.5 68.1 Compound 309 375 93.2 46.5 Compound 310 375 98.5 78.8 Compound311 347 345 97.6 52.4 Compound 312 361 95.9 50.7 Compound 313 363 100.593.2 Compound 314 401 101.7 100.1 Compound 315 341 100.1 85.0 Compound316 361 92.9 Compound 317 405 97.2 95.8 Compound 318 397 68.5 Compound319 337 93.4 89.9 Compound 320 341 93.5 47.9 Compound 321 395 100.4 99.7Compound 322 361 361 95.9 43.5 Compound 323 326 324 64.4 Compound 324431 88.1 Compound 325 324 324 36.5 Compound 326 402 Compound 327 402Compound 328 431 Compound 329 324 324 38.5 Compound 330 415 Compound 331408 406 406 23.9 Compound 332 339 35.5 Compound 333 329 329 92.8Compound 334 373 373 54.7 Compound 335 367 Compound 336 314 89.3Compound 337 351 102.3 61.3 Compound 338 367 103.0 69.4 Compound 339 344344 92.1 Compound 340 367 77.5 Compound 341 367 99.4 99.4 Compound 342315 88.4 Compound 343 381 98.9 41.4 Compound 344 380 101.8 65.8 Compound345 382 88.5 Compound 346 376 376 38.5 Compound 347 458 Compound 348 442Compound 349 401 401 Compound 350 402 Compound 351 427 Compound 352 427425 425 Compound 353 423 423 23.3 Compound 354 471 Compound 355 351100.9 62.8 Compound 356 410 Compound 357 414 85.6 Compound 358 414 79.6Compound 359 473 Compound 360 378 Compound 361 409 Compound 362 415 28.2Compound 363 377 377 100.4 Compound 364 422 27.0 Compound 365 350 36081.7 41.8 Compound 366 374 Compound 367 345 343 343 97.0 41.8 Compound368 355 365 101.7 85.1 Compound 369 365 105.3 102.0 Compound 370 38532.3 Compound 371 455 102.2 61.2 Compound 372 455 104.7 94.3 Compound373 310 310 73.4 Compound 374 377 375 Compound 375 92.6 54.3 Compound376 90.7 57.3 Compound 377 97.9 90.3 Compound 378 103.3 87.2 Compound379 99.7 93.4 Compound 380 104.7 85.2 Compound 381 97.1 94.9 Compound382 97.8 99.6 Compound 383 82.2 66.0 Compound 384 104.1 93.5 Compound385 99.9 90.1 Compound 386 103.0 99.5 Compound 387 101.8 99.3 Compound388 104.4 103.3 Compound 389 96.3 89.6 Compound 390 101.3 99.8 Compound391 92.5 78.3 Compound 392 95.6 85.1 Compound 393 82.4 65.3 Compound 39482.9 76.9 Compound 395 91.9 83.7 Compound 396 87.9 83.3 Compound 39788.6 92.0 Compound 398 85.8 93.5 Compound 399 88.5 90.9 Compound 40092.8 84.8 Compound 401 92.8 87.2 Compound 402 90.4 95.8 Compound 40386.1 85.9 Compound 404 91.2 90.0 Compound 405 90.4 88.2 Compound 40690.1 92.5 Compound 407 94.7 81.9 Compound 408 88.5 84.9 Compound 40988.1 92.2 Compound 410 96.4 86.1 Compound 411 95.9 81.8 Compound 41299.9 89.1 Compound 413 100.3 93.8 Compound 414 100.8 81.0 Compound 41599.6 75.1 Compound 416 100.0 77.7 Compound 417 97.9 64.8 Compound 41899.5 70.4 Compound 419 67.8 Compound 420 93.3 50.1 Compound 421 71.3Compound 422 47.5 Compound 423 59.2 Compound 424 58.7 Compound 425 83.6Compound 426 95.7 100.7 Compound 427 97.5 67.0 Compound 428 101.3 99.2Compound 429 95.1 74.2 Compound 430 97.9 89.2 Compound 431 98.0 94.6Compound 432 92.2 82.9 Compound 433 93.8 70.2 Compound 434 95.6 90.5Compound 435 93.7 86.4 Compound 436 94.5 49.0 Compound 437 101.1 93.9Compound 438 82.2 Compound 439 95.0 100.2 Compound 440 95.1 101.8Compound 441 14.7 Compound 442 40.2 Compound 443 31.3 43.0 Compound 44418.2 60.9 Compound 445 93.0 81.6 Compound 446 91.4 72.5 Compound 44789.2 72.2 Compound 448 89.7 99.6 Compound 449 91.6 65.9 Compound 45092.3 93.8 Compound 451 94.2 62.7 Compound 452 91.8 89.7 Compound 45389.4 97.1 Compound 454 91.7 92.6 Compound 455 93.2 91.7 Compound 45687.4 89.0 Compound 457 85.4 101.1 Compound 458 86.5 91.9 Compound 45989.9 68.5 Compound 460 94.5 76.3 Compound 461 87.9 89.5 Compound 46283.5 92.1 Compound 463 88.7 97.2 Compound 464 99.6 98.3 Compound 46597.9 88.0 Compound 466 99.3 88.8 Compound 467 100.4 98.6 Compound 46896.9 75.8 Compound 469 95.9 83.9 Compound 470 91.6 80.8 Compound 47196.5 91.0 Compound 472 102.0 94.4 Compound 473 95.1 91.7 Compound 47493.0 79.0 Compound 475 97.9 86.4 Compound 476 100.0 86.1 Compound 47792.0 77.1 Compound 478 104.4 86.0 Compound 479 93.3 83.0 Compound 48093.1 77.4 Compound 481 96.3 64.9 Compound 482 90.7 72.3 Compound 48388.9 Compound 484 102.0 63.2 Compound 485 103.2 95.5 Compound 486 99.593.8 Compound 487 99.6 90.4 Compound 488 101.9 91.4 Compound 489 103.398.4 Compound 490 100.7 88.9 Compound 491 88.9 75.7 Compound 492 104.387.9 Compound 493 104.7 88.3 Compound 494 102.5 87.1 Compound 495 104.189.9 Compound 496 103.2 75.7 Compound 497 102.0 66.5 Compound 498 103.688.5 Compound 499 106.7 89.1 Compound 500 102.7 81.6 Compound 501 102.355.4 Compound 502 107.6 86.3 Compound 503 103.9 73.3 Compound 504 96.654.0 Compound 505 102.9 74.4 Compound 506 88.6 Compound 507 96.7Compound 508 100.1 Compound 509 Compound 510 105.5 70.9 Compound 51199.0 85.4 Compound 512 105.3 71.5 Compound 513 98.8 55.2 Compound 51498.4 86.7 Compound 515 102.9 62.4 Compound 516 100.8 61.9 Compound 51793.7 42.7 Compound 518 83.5 Compound 519 Compound 520 Compound 521Compound 522 Compound 523 82.5 Compound 524 75.0 Compound 525 98.0Compound 526 88.9 Compound 527 89.7 Compound 528 94.0 Compound 529 100.2Compound 530 97.2 Compound 531 100.5 Compound 532 53.8 Compound 533 98.9Compound 534 98.3 Compound 535 102.1 Compound 536 98.4 Compound 537101.4 Compound 538 103.4 Compound 539 Compound 540 96.3 Compound 54197.1 75.8 Compound 542 99.9 92.3 Compound 543 93.1 101.4 Compound 54447.5 100.5 Compound 545 101.2 Compound 546 96.9 Compound 547 85.4Compound 548 99.8 Compound 549 99.7 Compound 550 98.6 Compound 551 100.9Compound 552 97.3 Compound 553 94.2 Compound 554 88.0 Compound 555Compound 556 Compound 557 Compound 558 Compound 559 Compound 560Compound 561 Compound 562 Compound 563 Compound 564 Compound 565Compound 566 Compound 567 Compound 568

INDUSTRIAL APPLICABILITY

The compound of the present invention is an excellent Edg-1(S1P₁)ligand. Hence, it is useful as an agent for the treatment or preventionof autoimmune diseases such as Crohn disease, irritable colitis, Sjögrensyndrome, multiple sclerosis, and systemic lupus erythematosus, anddiseases such as rheumatoid arthritis, asthma, atopic dermatitis,rejection reaction after organ transplantation, cancer, retinopathy,psoriasis, osteoarthrosis, and age-related macular degeneration.

1. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof

{where A represents an oxygen atom, R¹ represents an alkyl group having 1 to 16 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, an alkyl group having 1 to 6 carbon atoms that is substituted by any of the following groups (1) to (28) (1) (a) phenyl group(s); (2) a phenyl group substituted by 1 to 5 groups selected from (2-1) a phenyl group, (2-2) a cyano group, (2-3) a halogen atom, (2-4) an alkyl group having 1 to 6 carbon atoms, (2-5) a trifluoromethyl group, (2-6) a methoxycarbonyl group, (2-7) an alkylthio group having 1 to 6 carbon atoms, (2-8) a dimethylamino group, (2-9) a nitro group, and (2-10) an acetamido group; (3) a cycloalkyl group having 3 to 8 carbon atoms; (4) a hydroxyl group; (5) an alkylthio group having 1 to 6 carbon atoms; (6) an alkoxy group having 1 to 6 carbon atoms; (7) a benzyloxy group; (8) a phenoxy group; (9) a trifluoromethyl group; (10) a difluoromethyl group; (11) a benzenesulfonyl group; (12) a naphthyl group; (13) a tricycloalkyl group having 7 to 10 carbon atoms; (14) a 1-phenylethyl group, (15) an imidazolyl group; (16) an indolyl group; (17) a pyridyl group; (18) an oxetanyl group; (19) an oxoranyl group; (20) a methylpiperidinyl group; (21) a benzylpiperidinyl group; (22) a morpholino group; (23) a 2-oxopyrrolidin-1-yl group; (24) a 2-oxoimidazolidin-1-yl group; (25) a group represented by the formula —CO₂R¹¹; where R¹¹ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; (26) a group represented by the following chemical formula 2:

where R¹² and R¹³ each represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, (27) a group represented by the following chemical formula 3

where R¹⁴ and R¹⁵ each represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a phenyl group, or a 4-pyridylcarbonyl group; and (28) a group represented by the formula —COR¹⁶ where R¹⁶ represents (28-1) an alkyl group having 1 to 6 carbon atoms, or (28-2) a phenyl group; an alkenyl group having 2 to 8 carbon atoms that is substituted by a phenyl group or a benzyloxy group, an alkynyl group having 2 to 8 carbon atoms which has been substituted by a phenyl group, a cycloalkyl group having 3 to 8 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms in which the benzene rings have been condensed, an oxoranyl group, a methylpiperidinyl group, or a group represented by the formula 4

R² represents an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms, a phenyl group, or an alkyl group having 1 to 6 carbon atoms which is substituted by any of the following groups (29) to (34): (29) a phenyl group; (30) an alkoxy group having 1 to 6 carbon atoms; (31) a morpholino group; (32) a piperidino group; (33) a group represented by the following chemical formula 5:

where R²¹ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and (34) a group represented by the following chemical formula 6

where R²² and R²³ each represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R³ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R⁴ represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, a benzyl group that is substituted by 1 to 2 groups selected from the following groups (a) to (f): (a) a phenyl group, (b) a halogen atom, (c) a methyl group, (d) a methoxy group, (e) a trifluoromethyl group and (f) a hydroxyl group; a phenethyl group, an alkyl group having 1 to 6 carbon atoms substituted by a group selected from the following (g) to (i): (g) an alkoxy group having 1 to 6 carbon atoms, (h) a halogen atom, and (i) a hydroxyl group; or a phenyl group, or R³ and R⁴ together form a 3- to 6-membered saturated hydrocarbon ring, R⁵ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and Y represents a group represented by the formula

where R⁶ represents an alkyl group having 1 to 10 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkyl group having 1 to 10 carbon atoms that is substituted with 1 to 5 groups selected from the following groups (j) to (p): (j) a phenyl group, (k) a phenyl group substituted with 1 to 5 substituents selected from the following substituents (k-1) to (k-37): (k-1) a phenyl group, (k-2) a phenyl group substituted with a methoxy group or an acetyl group, (k-3) an oxazolyl group, (k-4) a pyrazolyl group, (k-5) a methylpyrimidinyl group, (k-6) a cyano group, (k-7) a halogen atom, (k-8) an alkyl group having 1 to 6 carbon atoms, (k-9) a trifluoromethyl group; (k-10) a trifluoromethoxy group, (k-11) a difluoromethoxy group, (k-12) a hydroxyl group, (k-13) an alkoxy group having 1 to 6 carbon atoms, (k-14) a cyanoethoxy group, (k-15) a phenoxy group, (k-16) a phenoxy group substituted with a methoxy group, (k-17) a pyridinyloxy group, (k-18) an acetyl group, (k-19) a benzoyl group, (k-20) a pyridinecarbonyl group, (k-21) a methoxycarbonyl group, (k-22) a methoxycarbonylethyl group, (k-23) an akylthio group having 1 to 6 carbon atoms, (k-24) a dimethylamino group, (k-25) a nitro group, (k-26) an acetamido group, (k-27) a sulfamoyl group, (k-28) a methanesulfonyl group, (k-29) a benzenesulfonyl group, (k-30) a pyrrolidinesulfonyl group, (k-31) a morpholinesulfonyl group, (k-32) a methylureido group, (k-33) a butylureido group, (k-34) a methoxyethylureido group, (k-35) a trimethylureido group, (k-36) a morpholinecarbonylamino group, and (k-37) a pyridinylethoxycarbonylamino group; (l) a cycloalkyl group having 3 to 8 carbon atoms, (m) a halogen atom,(n) a naphthyl group, (o) a heterocyclic group, and (p) a heterocyclic group substituted with 1 to 5 substitutes selected from the following groups (p-1) to (p-6): (p-1) a halogen atom, (p-2) an alkyl group having 1 to 6 carbon atoms, (p-3) a methoxycarbonyl group, (p-4) an ethoxcarbonyl group (p-5) a benzenesulfonyl group, and (p-6) an oxazolyl group; an alkenyl group having 2 to 8 carbon atoms that is substituted by 1 to 5 groups selected from the groups (j) to (p) mentioned above as substituents of the alkyl group; a phenyl group, a phenyl group that is substituted with 1 to 5 substituents selected from the above groups of substituents (k-1) to (k-37), a naphthyl group, a naphthyl group substituted by a dimethylamino group, a heterocyclic group, or a heterocyclic group substituted with 1 to 5 substituents selected from the above groups (p-1) to (p-6).
 2. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (I) R¹ represents an alkyl group having 1 to 16 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, an alkyl group having 1 to 6 carbon atoms that is substituted with any of the following groups (1) to (30) (1) a phenyl group(s); (2) a phenyl group substituted by 1 to 2 groups selected from (2-1) a phenyl group, (2-2) a cyano group, (2-3) a halogen atom, (2-4) an alkyl group having 1 to 6 carbon atoms, (2-5) a trifluoromethyl group, (2-6) a methoxycarbonyl group, (2-7) an alkylthio group having 1 to 6 carbon atoms, (2-8) a dimethylamino group, (2-9) a nitro group, and (2-10) an acetamido group; (3) a cycloalkyl group having 3 to 8 carbon atoms; (4) a hydroxyl group; (5) an alkylthio group having 1 to 6 carbon atoms; (6) an alkoxy group having 1 to 6 carbon atoms; (7) a benzyloxy group; (8) a phenoxy group; (9) a trifluoromethyl group; (10) a difluoromethyl group; (11) a benzenesulfonyl group; (12) a naphthyl group; (13) a tricycloalkyl group having 7 to 10 carbon atoms; (14) a 1-phenylethyl group; (15) a 1-imidazolyl group; (16) a 3-indolyl group; (17) a 2-pyridyl group; (18) a 4-pyridyl group; (19) a 2-oxetanyl group; (20) a 3-oxoranyl group; (21) a 3-methylpiperidinyl group; (22) a 4-methylpiperidinyl group; (23) a 4-benzylpiperidinyl group; (24) a morpholino group; (25) a 2-oxopyrrolidin-1-yl group; (26) a 2-oxoimidazolidin-1-yl group; (27) a group represented by the formula —CO₂R¹¹ where R¹¹ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, (28) a group represented by the formula 2:

where R¹² and R¹³ each represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, (29) a group represented by the formula 3

where R¹⁴ and R¹⁵ each represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a phenyl group, or a 4-pyridylcarbonyl group, and (30) a group represented by the formula —COR¹⁶ where R¹⁶ represents an alkyl group having 1 to 6 carbon atoms, or a phenyl group, an alkenyl group having 2 to 8 carbon atoms which has been substituted by a phenyl group or a benzyloxy group, an alkynyl group having 2 to 8 carbon atoms which has been substituted by a phenyl group, a cycloalkyl group having 3 to 8 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms in which the benzene rings have been condensed, an oxoranyl group, a 4-methylpiperidinyl group, or a group represented by the formula 4


3. The compound or the pharmaceutically acceptable salt thereof according to claim 2, wherein in the formula (I) R⁵ is a hydrogen atom.
 4. The compound or the pharmaceutically acceptable salt thereof according to claim 2, wherein in the formula (I) R² is an alkyl group having 1 to 4 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, or an alkyl group having 1 to 4 carbon atoms that is substituted by a methoxy group or a morpholino group.
 5. The compound or the pharmaceutically acceptable salt thereof according to claim 2, wherein in the formula (I) R² is a methyl group, an ethyl group, an isopropyl group, or a cyclopropyl group.
 6. The compound or the pharmaceutically acceptable salt thereof according to claim 2, wherein in the formula (I) R³ is a hydrogen atom.
 7. The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein in the formula (I) R⁴ is a methyl group, an ethyl group, a benzyl group, or a benzyl group that is substituted by 1 to 2 groups selected from the following groups (a) to (f): (a) a phenyl group, (b) a halogen atom, (c) a methyl group, (d) a methoxy group, (e) a trifluoromethyl group and (f) a hydroxyl group.
 8. The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein in the formula (I) R⁴ is a methyl group, a benzyl group, or a benzyl group mono- or di-substituted by a substituent selected from a halogen atom and a methyl group.
 9. The compound or the pharmaceutically acceptable salt thereof according to claim 8, wherein in the formula (I) R² is a methyl group, an ethyl group, an isopropyl group, or a cyclopropyl group.
 10. The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein in the formula (I) R¹ is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 3 to 5 carbon atoms, a 2-propynyl group, a cycloalkyl group having 3 to 6 carbon atoms, or an alkyl group having 1 to 6 carbon atoms that is substituted by a cycloalkyl group having 3 to 6 carbon atoms, a trifluoromethyl group, a phenyl group, a hydroxyl group, a methoxy group, a dimethylamino group, or a morpholino group.
 11. The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein in the formula (I) R¹ is a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclopropylmethyl group, or a 3-methoxypropyl group.
 12. The compound or the pharmaceutically acceptable salt thereof according to claim 11, wherein in the formula (I) R⁴ is a methyl group, a benzyl group, or a benzyl group mono- or di-substituted by a substituent selected from a halogen atom and a methyl group.
 13. The compound or the pharmaceutically acceptable salt thereof according to claim 12, wherein in the formula (I) R² is a :methyl group, an ethyl group, an isopropyl group, or a cyclopropyl group.
 14. The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein in the formula (I) R⁶ is a phenyl group, a phenyl group substituted by 1 to 3 groups selected from a halogen atom, an alkyl group having 1 to 4 carbon atoms, a trifluoromethyl group, an alkoxy group having 1 to 6 carbon atoms, a trifluoromethoxy group, a difluoromethyl group, an acetyl group, a nitro group, and a cyano group, a 2-naphthyl group, a 2-benzothienyl group, a 2-benzofuranyl group, a 2-thienyl group substituted by 1 or 2 halogen atoms, or a benzo[1,2,5]thiadiazolyl group.
 15. The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein in the formula (I) R⁶ is a phenyl group, “a phenyl group substituted by 1 or 2 groups selected from a halogen atom, a methyl group, a trifluoromethyl group, a methoxy group, and a trifluoromethoxy group, a 2-naphthyl group, a 2-benzothienyl group, or a 2-benzofuranyl group.
 16. The compound or the pharmaceutically acceptable salt thereof according to claim 15, wherein in the formula (I) R¹ is a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclopropylmethyl group, or a 3-methoxypropyl group.
 17. The compound or the pharmaceutically acceptable salt thereof according to claim 16, wherein in the formula (I) R⁴ is a methyl group, a benzyl group, or a benzyl group mono- or di-substituted by a substituent selected from a halogen atom and a methyl group.
 18. The compound or the pharmaceutically acceptable salt thereof according to claim 17, wherein in the formula (I) R² is a methyl group, an ethyl group, an isopropyl group, or a cyclopropyl group.
 19. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof

where A represents an oxygen atom, R¹ represents an alkyl group having 1 to 16 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, an alkyl group having 1 to 6 carbon atoms that is substituted by any of the following groups (1) to (30): (1) a phenyl group(s); (2) a phenyl group substituted by 1 to 2 groups selected from (2-1) a phenyl group, (2-2) a cyano group, (2-3) a halogen atom, (2-4) an alkyl group having 1 to 6 carbon atoms, (2-5) a trifluoromethyl group, (2-6) a methoxycarbonyl group, (2-7) an alkylthio group having 1 to 6 carbon atoms, (2-8) a dimethylamino group, (2-9) a nitro group, and (2-10) an acetamido group; (3) a cycloalkyl group having 3 to 8 carbon atoms; (4) a hydroxyl group; (5) an alkylthio group having 1 to 6 carbon atoms; (6) an alkoxy group having 1 to 6 carbon atoms; (7) a benzyloxy group; (8) a phenoxy group; (9) a trifluoromethyl group; (10) a difluoromethyl group; (11) a benzenesulfonyl group; (12) a naphthyl group; (13) a tricycloalkyl group having 7 to 10 carbon atoms; (14) a 1-phenylethyl group; (15) a 1-imidazolyl group; (16) a 3-indolyl group; (17) a 2-pyridyl group; (18) a 4-pyridyl group; (19) a 2-oxetanyl group; (20) a 3-oxoranyl group; (21) a 3-methylpiperidinyl group; (22) a 4-methylpiperidinyl group; (23) a 4-benzylpiperidinyl group; (24) a morpholino group; (25) a 2-oxopyrrolidin-1-yl group; (26) a 2-oxoimidazolidin-1-yl group; (27) a group represented by the formula —CO₂R¹¹; where R¹¹ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; (28) a group represented by the following chemical formula 2

where R¹² and R¹³ each represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, (29) a group represented by the formula 3

where R¹⁴ and R¹⁵ each represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a phenyl group, or a 4-pyridylcarbonyl group, and (30) a group represented by the formula —COR¹⁶, where R¹⁶ represents (30-1) an alkyl group having 1 to 6 carbon atoms, or (30-2) a phenyl group; an alkenyl group having 2 to 8 carbon atoms which has been substituted by a phenyl group or a benzyloxy group, an alkynyl group having 2 to 8 carbon atoms which has been substituted by a phenyl group, a cycloalkyl group having 3 to 8 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms in which the benzene rings have been condensed, an oxoranyl group, a methylpiperidinyl group, or a group represented by the formula 4

R² represents an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms, a phenyl group, or an alkyl group having 1 to 6 carbon atoms that is substituted by a group selected from the following groups (1) to (6): (1) a phenyl group, (2) an alkoxy group having 1 to 6 carbon atoms, (3) a morpholino group, (4) a piperidino group, (5) a group represented by the formula

where R²¹ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and (6) a group represented by the formula

where R²² and R²³ each represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R³ represents a hydrogen atom, R⁴ represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, a benzyl group that is substituted by 1 to 2 groups selected from the following groups (a) to (f): (a) a phenyl group, (b) a halogen atom, (c) a methyl group, (d) a methoxy group, (e) a trifluoromethyl group and (f) a hydroxyl group; a phenethyl group, an alkyl group having 1 to 6 carbon atoms that is substituted with (g) an alkoxy group having 1 to 6 carbon atoms, (h) a halogen atom or (i) a hydroxyl group; or a phenyl group; or R³ and R⁴ together form a 3- to 6-membered saturated hydrocarbon ring; R⁵ represents a hydrogen atom, and Y represents a hydrogen atom.
 20. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof,

where A represents an oxygen atom, R¹ represents an alkyl group having 1 to 16 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, an alkyl group having 1 to 6 carbon atoms that is substituted by any of the following groups (1) to (30): (1) a phenyl group(s); (2) a phenyl group substituted by 1 to 2 groups selected from (2-1) a phenyl group, (2-2) a cyano group, (2-3) a halogen atom, (2-4) an alkyl group having 1 to 6 carbon atoms, (2-5) a trifluoromethyl group, (2-6) a methoxycarbonyl group, (2-7) an alkylthio group having 1 to 6 carbon atoms, (2-8) a dimethylamino group, (2-9) a nitro group, and (2-10) an acetamido group; (3) a cycloalkyl group having 3 to 8 carbon atoms; (4) a hydroxyl group; (5) an alkylthio group having 1 to 6 carbon atoms; (6) an alkoxy group having 1 to 6 carbon atoms; (7) a benzyloxy group; (8) a phenoxy group; (9) a trifluoromethyl group; (10) a difluoromethyl group; (11) a benzenesulfonyl group; (12) a naphthyl group; (13) a tricycloalkyl group having 7 to 10 carbon atoms; (14) a 1-phenylethyl group; (15) a 1-imidazolyl group; (16) a 3-indolyl group; (17) a 2-pyridyl group; (18) a 4-pyridyl group; (19) a 2-oxetanyl group; (20) a 3-oxoranyl group; (21) a 3-methylpiperidinyl group; (22) a 4-methylpiperidinyl group; (23) a 4-benzylpiperidinyl group; (24) a morpholino group; (25) a 2-oxopyrrolidin-1-yl group; (26) a 2-oxoimidazolidin-1-yl group; (27) a group represented by the formula —CO₂R¹¹; where R¹¹ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; (28) a group represented by the following chemical formula 2

where R¹² and R¹³ each represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, (29) a group represented by the formula 3

where R¹⁴ and R¹⁵ each represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a phenyl group, or a 4-pyridylcarbonyl group, (30) a group represented by the formula —COR¹⁶, where R¹⁶ represents (30-1) an alkyl group having 1 to 6 carbon atoms, or (30-2) a phenyl group, an alkenyl group having 2 to 8 carbon atoms that is substituted by a phenyl group or a benzyloxy group, an alkynyl group having 2 to 8 carbon atoms which has been substituted by a phenyl group, a cycloalkyl group having 3 to 8 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms in which the benzene rings have been condensed, an oxoranyl group, a 4-methylpiperidinyl group, or a group represented by the formula 4

R² represents an alkyl group having 1 to 4 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, or an alkyl group having 1 to 4 carbon atoms that is substituted by a methoxy group or a morpholino group, R³ represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R⁴ represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, a benzyl group that is substituted by 1 to 2 groups selected from the following groups (a) to (f): (a) a phenyl group, (b) a halogen atom, (c) a methyl group, (d) a methoxy group, (e) a trifluoromethyl group and (f) a hydroxyl group; a phenethyl group, an alkyl group having 1 to 6 carbon atoms that is substituted with (g) an alkoxy group having 1 to 6 carbon atoms, (h) a halogen atom or (i) a hydroxyl group; or a phenyl group; or R³ and R⁴ together form a 3- to 6-membered saturated hydrocarbon ring; R⁵ represents a hydrogen atom, and Y represents a hydrogen atom.
 21. The compound or the pharmaceutically acceptable salt thereof according to claim 20 wherein in the formula (I) R² is a methyl group, an ethyl group, an isopropyl group, or a cyclopropyl group.
 22. The compound or the pharmaceutically acceptable salt thereof according to claim 19, wherein in the formula (I) R⁴ is a methyl group, a benzyl group, or a benzyl group mono- or di-substituted by a substituent selected from a halogen atom and a methyl group, and R² is a methyl group, an ethyl group, an isopropyl group, or a cyclopropyl group.
 23. The compound or the pharmaceutically acceptable salt thereof according to claim 19, wherein in the formula (I) R¹ is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 3 to 5 carbon atoms, a 2-propynyl group, a cycloalkyl group having 3 to 6 carbon atoms, or an alkyl group having 1 to 6 carbon atoms which has been substituted by a cycloalkyl group having 3 to 6 carbon atoms, a trifluoromethyl group, a phenyl group, a hydroxyl group, a methoxy group, a dimethylamino group, or a morpholino group.
 24. The compound or the pharmaceutically acceptable salt thereof according to claim 19, wherein in the formula (I) R¹ is a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclopropylmethyl group, or a 3-methoxypropyl group.
 25. The compound or the pharmaceutically acceptable salt thereof according to claim 24, wherein in the formula (I) R⁴ is a methyl group, a benzyl group, or a benzyl group mono- or di-substituted by a substituent selected from a halogen atom and a methyl group.
 26. The compound or the pharmaceutically acceptable salt thereof according to claim 25, wherein in the formula (I) R² is a methyl group, an ethyl group, an isopropyl group, or a cyclopropyl group. 